<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Amantadine and rimantadine for influenza A in children and the elderly - Alves Galvão, MG - 2014 | Cochrane Library</title> <meta content="Amantadine and rimantadine for influenza A in children and the elderly - Alves Galvão, MG - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002745.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Amantadine and rimantadine for influenza A in children and the elderly - Alves Galvão, MG - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002745.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002745.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Amantadine and rimantadine for influenza A in children and the elderly" name="citation_title"/> <meta content="Márcia G Alves Galvão" name="citation_author"/> <meta content="Municipal Secretariat of Health" name="citation_author_institution"/> <meta content="Marilene Augusta Rocha Crispino Santos" name="citation_author"/> <meta content="Municipal Secretariat of Health" name="citation_author_institution"/> <meta content="Antonio JL Alves da Cunha" name="citation_author"/> <meta content="School of Medicine, Federal University of Rio de Janeiro" name="citation_author_institution"/> <meta content="acunha@hucff.ufrj.br" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD002745.pub4" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/11/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002745.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002745.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002745.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Influenza A virus; Amantadine [adverse effects, *therapeutic use]; Antiviral Agents [adverse effects, *therapeutic use]; Influenza A Virus, H1N1 Subtype; Influenza, Human [*prevention &amp; control]; Randomized Controlled Trials as Topic; Rimantadine [adverse effects, *therapeutic use]; Sex Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002745.pub4&amp;doi=10.1002/14651858.CD002745.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="jU9oKp1Y";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002745\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002745\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002745.pub4",title:"Amantadine and rimantadine for influenza A in children and the elderly",firstPublishedDate:"Nov 21, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002745.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002745.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002745.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002745.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002745.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002745.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002745.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002745.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002745.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002745.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4177 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002745.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full#CD002745-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full#CD002745-sec-0087"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full#CD002745-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full#CD002745-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full#CD002745-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full#CD002745-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full#CD002745-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full#CD002745-sec-0081"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/appendices#CD002745-sec-0096"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/table_n/CD002745StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/table_n/CD002745StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Amantadine and rimantadine for influenza A in children and the elderly</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/information#CD002745-cr-0002">Márcia G Alves Galvão</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/information#CD002745-cr-0003">Marilene Augusta Rocha Crispino Santos</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002745.pub4/information#CD002745-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Antonio JL Alves da Cunha</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/information/en#CD002745-sec-0108">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 November 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002745.pub4">https://doi.org/10.1002/14651858.CD002745.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002745-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002745-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002745-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002745-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002745-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002745-abs-0001" lang="en"> <section id="CD002745-sec-0001"> <h3 class="title" id="CD002745-sec-0001">Background</h3> <p>Influenza is an acute respiratory illness caused by influenza A and B viruses. Complications may occur, especially among children and the elderly. </p> </section> <section id="CD002745-sec-0002"> <h3 class="title" id="CD002745-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of amantadine and rimantadine in preventing, treating and shortening the duration of influenza A in children and the elderly. </p> </section> <section id="CD002745-sec-0003"> <h3 class="title" id="CD002745-sec-0003">Search methods</h3> <p>We searched CENTRAL (2014, Issue 9), MEDLINE (1966 to September week 4, 2014) and EMBASE (1980 to October 2014). </p> </section> <section id="CD002745-sec-0004"> <h3 class="title" id="CD002745-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) or quasi‐RCTs comparing amantadine and/or rimantadine with no intervention, placebo, other antivirals or different doses or schedules of amantadine or rimantadine in children and the elderly with influenza A. </p> </section> <section id="CD002745-sec-0005"> <h3 class="title" id="CD002745-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed the search results. We extracted and analysed data using the standard Cochrane methodology. </p> </section> <section id="CD002745-sec-0006"> <h3 class="title" id="CD002745-sec-0006">Main results</h3> <p>We identified 12 studies (2494 participants: 1586 children and 908 elderly) comparing amantadine and rimantadine with placebo, paracetamol (one trial: 69 children) or zanamivir (two trials: 545 elderly) to treat influenza A. </p> <p>Amantadine was effective in preventing influenza A in children (773 participants, risk ratio (RR) 0.11; 95% confidence interval (CI) 0.04 to 0.30). The assumed risk of influenza A in the control group was 10 per 100. The corresponding risk in the rimantadine group was one per 100 (95% CI 0 to 3). Nevertheless, the quality of the evidence was low and the safety of the drug was not well established. </p> <p>For treatment, rimantadine was beneficial in abating fever on day three of treatment in children: one selected study with low risk of bias, moderate evidence quality and 69 participants (RR 0.36; 95% CI 0.14 to 0.91). The assumed risk was 38 per 100. The corresponding risk in the rimantadine group was 14 per 100 (95% CI 5 to 34). </p> <p>Rimantadine did not show any prophylactic effect in the elderly. The quality of evidence was very low: 103 participants (RR 0.45; 95% CI 0.14 to 1.41). The assumed risk was 17 per 100. The corresponding risk in the rimantadine group was 7 per 100 (95% CI 2 to 23). </p> <p>There was no evidence of adverse effects caused by treatment with amantadine or rimantadine.</p> <p>We found no studies assessing amantadine in the elderly.</p> </section> <section id="CD002745-sec-0007"> <h3 class="title" id="CD002745-sec-0007">Authors' conclusions</h3> <p>The quality of the evidence combined with a lack of knowledge about the safety of amantadine and the limited benefits of rimantadine, do not indicate that amantadine and rimantadine compared to control (placebo or paracetamol) could be useful in preventing, treating and shortening the duration of influenza A in children and the elderly. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002745-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002745-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002745-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002745-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002745-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002745-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002745-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002745-abs-0004" lang="en"> <h3>Amantadine and rimantadine to prevent and treat influenza A in children and the elderly</h3> <p><b>Review question</b> </p> <p>As recommended by the World Health Organization (WHO), oseltamivir (Tamiflu) is currently used for people with influenza A. In previous pandemics, the virus was susceptible to amantadine and rimantadine. If they are safe and the circulating strain proves to be susceptible to these drugs, they could be an alternative for managing influenza. We therefore wanted to answer the question of whether or not amantadine and rimantadine can prevent and treat influenza A in children and the elderly. </p> <p><b>Background</b> </p> <p>Influenza A is a respiratory infection causing cough, runny nose and fever. Most symptoms pass without treatment within three to seven days. However, hospitalisation, pneumonia and even death are rare complications of the illness, especially among children and the elderly. Pandemics are also a cause for concern. </p> <p><b>Key results and quality of the evidence</b> </p> <p>We identified 12 trials (2494 participants: 1586 children and 908 elderly). We looked for trials that compared amantadine or rimantadine with no intervention, placebos or control drugs in children and the elderly. The most recent searches were completed in October 2014. We looked at several outcomes, including influenza A, fever duration, cough, headache, nausea/vomiting, dizziness and stimulation/insomnia. </p> <p>Although amantadine was effective in preventing influenza A in children, it would be necessary to use it in up to 17 children over a period of 14 to 18 weeks to prevent one case of influenza A. Furthermore, the safety of the drug was not well established. The quality of the evidence was low. </p> <p>The effectiveness of both antivirals was limited to a benefit from rimantadine in the reduction of fever by day three of treatment in children. The quality of the evidence was moderate. This benefit does not seem to justify a recommendation for using rimantadine to treat all children with influenza A. </p> <p>Rimantadine did not show a prophylactic (preventative) effect in the elderly. The quality of evidence was very low. </p> <p><b>Conclusion</b> </p> <p>The quality of the evidence combined with a lack of knowledge about the safety of amantadine and the limited benefits of rimantadine, do not indicate that amantadine and rimantadine compared to control (placebo or paracetamol) could be useful in preventing, treating and shortening the duration of influenza A in children and the elderly. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002745-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002745-sec-0087"></div> <h3 class="title" id="CD002745-sec-0088">Implications for practice</h3> <section id="CD002745-sec-0088"> <p>The quality of evidence currently available does not provide strong support for amantadine and rimantadine use to treat and prevent influenza in children and the elderly. </p> <p>Amantadine was effective in preventing influenza A in children but the safety of the drug was not well established. Currently, rimantadine cannot be recommended as a prophylactic drug for either age group. Nevertheless, if we consider: 1) that it is a safe drug, 2) the results of the combined age groups and 3) the possibility that the next pandemic virus is susceptible to this class of drug, as indicated in former pandemics, we can still consider this 'old' drug as a less costly alternative to neuraminidase inhibitors. </p> <p>Our conclusions regarding the effectiveness of both antivirals for the treatment of influenza A in children were limited to a proven benefit of rimantadine in the abatement of fever by day three of treatment. This benefit does not seem to justify a recommendation for using rimantadine to treat all children with influenza A. We could not reach a conclusion regarding amantadine in the elderly, or antiviral treatment in this age group, as no trials fulfilled our selection criteria. </p> </section> <h3 class="title" id="CD002745-sec-0089">Implications for research</h3> <section id="CD002745-sec-0089"> <p>Definitive conclusions may have been impaired by the small number of selected studies and the small sample numbers used. Further research is necessary for the following. </p> <section id="CD002745-sec-0090"> <h5 class="title">Treatment</h5> <p> <ul id="CD002745-list-0007"> <li> <p>Amantadine for the treatment of influenza A in children to increase the sample numbers and the power of the studies. </p> </li> <li> <p>Rimantadine for the treatment of influenza A in children in order to confirm the observed result from the only selected study and to see if the drug could be useful in treating other clinical manifestations of influenza. </p> </li> <li> <p>Amantadine and rimantadine for the treatment of influenza A in the elderly, as no identified studies fulfilled our inclusion criteria. </p> </li> </ul> </p> </section> <section id="CD002745-sec-0091"> <h5 class="title">Prophylaxis</h5> <p> <ul id="CD002745-list-0008"> <li> <p>Rimantadine in children to increase the sample numbers and the power of the studies, in order to achieve more definitive conclusions. </p> </li> <li> <p>Amantadine in the elderly, as there were no identified studies fulfilling our inclusion criteria for this age group. </p> </li> <li> <p>Rimantadine in the elderly to increase the sample numbers and the power of the studies, in order to achieve more definitive conclusions. </p> </li> </ul> </p> </section> <section id="CD002745-sec-0092"> <h5 class="title">Adverse effects</h5> <p> <ul id="CD002745-list-0009"> <li> <p>Amantadine in children without influenza to avoid confounding adverse reactions of the antiviral with clinical manifestations of influenza. </p> </li> <li> <p>Rimantadine in the elderly to increase the sample numbers and the power of the studies.</p> </li> </ul> </p> </section> <section id="CD002745-sec-0093"> <h5 class="title">Different doses of amantadine and rimantadine</h5> <p> <ul id="CD002745-list-0010"> <li> <p>Further information is necessary on both drugs in both age groups.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002745-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002745-sec-0022"></div> <div class="table" id="CD002745-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Amantadine compared with placebo for prevention and treatment of influenza A in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with no influenza A infection (prevention) or with influenza A infection (treatment) </p> <p><b>Settings:</b> all </p> <p><b>Intervention:</b> amantadine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Amantadine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cases of influenza A during prophylaxis</b> </p> <p>(follow‐up:14 to 18 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.11</b> (0.04 to 0.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>773<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> <br/> (0 to 3) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fever after initiation of treatment</b> </p> <p>(follow‐up: 3 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.37</b> (0.08 to 1.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>104<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 100</b> <br/> (2 to 40) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cough after initiation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dizziness</b> </p> <p>(follow‐up: 7 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 6.63</b> (0.32 to 137.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>599<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nausea/vomiting</b> </p> <p>(follow‐up: 7 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.54</b> (0.15 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>599<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>3,4,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> <br/> (2 to 27) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stimulation/insomnia</b> </p> <p>(follow‐up: 7 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.46</b> (0.12 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>599<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> <br/> (2 to 27) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) was calculated on the basis of control event rate. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><sup>1</sup>Allocation concealment not used or unclear. </p> <p><sup>2</sup>Sparse data. </p> <p><sup>3</sup>Allocation concealment unclear. </p> <p><sup>4</sup>Sparse data, confidence intervals do not rule out potential for null effect or harm. </p> <p><sup>5</sup>High heterogeneity unexplained. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002745-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Rimantadine compared with placebo for prevention and treatment of influenza A in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with no influenza A infection (prevention) or with influenza A infection (treatment) </p> <p><b>Settings:</b> any </p> <p><b>Intervention:</b> rimantadine </p> <p><b>Comparison:</b> control (placebo or acetaminophen) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Rimantadine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cases of influenza A during prophylaxis</b> (follow‐up: 1 to 35 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.49</b> (0.21 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>178<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 100</b> <br/> (5 to28) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fever after initiation of treatment</b> </p> <p>(follow‐up: 3 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.36</b> (0.14 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>69<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b> <br/> (5 to 34) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cough after initiation of treatment</b> </p> <p>(follow‐up: 7 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b> (0.63 to 1.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>69<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 100</b> <br/> (51 to 89) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dizziness</b> </p> <p>(follow‐up: 35 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.21</b> (0.14 to 75.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>56<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nausea/vomiting</b> </p> <p>(follow‐up: 7 to 35 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.96</b> (0.1 to 9.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> <br/> (0 to 15) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stimulation/insomnia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) was calculated on the basis of control event rate. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><sup>1</sup>Allocation concealment unclear. </p> <p><sup>2</sup>Sparse data and confidence intervals do not rule out the potential for no effect or harm </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002745-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Amantadine compared with placebo for prevention and treatment of influenza A in the elderly</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> elderly people with no influenza A infection (prevention) or with influenza A infection (treatment) </p> <p><b>Settings:</b> any </p> <p><b>Intervention:</b> amantadine </p> <p><b>Comparison:</b> control </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Amantadine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases of influenza A during prophylaxis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever after initiation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cough after initiation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dizziness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vomiting</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stimulation/insomnia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD002745-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> elderly people with no influenza A infection (prevention) or with influenza A infection (treatment) </p> <p><b>Settings:</b> any </p> <p><b>Intervention:</b> rimantadine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Rimantadine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cases of influenza A during prophylaxis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.45</b> (0.14 to 1.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>103<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> <br/> (2 to 23) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever after initiation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cough after initiation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dizziness</b> </p> <p>(follow‐up: 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 100 (2 to 70)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/> (0.15 to 5.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nausea</b> </p> <p>(follow‐up: 8 to 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.99</b> (0.45 to 8.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>233<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 100</b> <br/> (3 to 66) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Vomiting</b> </p> <p>(follow‐up: 8 to 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.99</b> (0.38 to 2.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>233<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> <br/> (3 to 17) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stimulation/insomnia</b> (follow‐up: 8 to 12 weeks) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.61</b> (0.43 to 6.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>233<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 100</b> <br/> (3 to 40) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) was calculated on the basis of control event rate. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><sup>1</sup>Allocation concealment unclear and 1 study had high withdrawal rate. </p> <p><sup>2</sup>Sparse data and confidence interval do not rule out no effect or harm. </p> <p><sup>3</sup>Allocation concealment unclear </p> <p><sup>4</sup>High heterogeneity unexplained. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002745-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002745-sec-0023"></div> <section id="CD002745-sec-0024"> <h3 class="title" id="CD002745-sec-0024">Description of the condition</h3> <p>Influenza is an acute and usually self limiting respiratory illness caused by influenza A and B viruses, which are members of the <i>Orthomyxoviridae</i> family (<a href="./references#CD002745-bbs2-0254" title="NicholsonK . Clinical features of influenza. Seminars in Respiratory Infections1992;7(1):26‐37. ">Nicholson 1992</a>). Influenza may cause annual epidemics and intermittent pandemics (<a href="./references#CD002745-bbs2-0258" title="SasakiS , SullivanM , NarvaezC , HolmesT , FurmanD , ZhengNY , et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine‐specific antibodies. Journal of Clinical Investigation2011;121(8):3109‐19. ">Sasaki 2011</a>). Typically, seasonal influenza occurs most frequently during autumn and winter in temperate regions, but in some tropical countries it may occur throughout the year with one or two peaks during rainy seasons (<a href="./references#CD002745-bbs2-0251" title="MontoAS . Epidemiology of influenza. Vaccine2008;Suppl(4):D45–8. ">Monto 2008</a>; <a href="./references#CD002745-bbs2-0271" title="YangM , DongBR , WuHM , LiT , LiuGJ . Interventions for treating influenza: an overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD008799] ">Yang 2010</a>). </p> <p>Although the natural transmission of the influenza virus predominantly occurs via aerosols dispersed by coughing or sneezing, it is also transmitted by nasal secretions and contact with contaminated surfaces. While all respiratory viruses, including influenza, use the nose as the entry channel, they can also enter through the tear ducts, draining into patients' sinuses and airways (<a href="./references#CD002745-bbs2-0228" title="BitkoV , MusiyenkoA , BarikS . Viral infection of the lungs through the eye. Journal of Virology2007;81:783‐90. ">Bitko 2007</a>). The virus particles are deactivated by the ultraviolet rays in sunlight and common disinfectants such as soap (<a href="./references#CD002745-bbs2-0227" title="BarikS . New treatments for influenza. BMC Medicine2012;13(10):104. ">Barik 2012</a>). </p> <p>The illness is characterised by an abrupt onset of symptoms. These symptoms include headache, fever, general aches, weakness and myalgia, accompanied by respiratory tract signs, particularly cough and sore throat. However, a wide spectrum of clinical presentations may occur, ranging from a mild, febrile upper respiratory illness, to severe prostration and respiratory and systemic signs and symptoms. </p> <p>The most common complication that occurs during outbreaks of influenza is pneumonia (both viral and bacterial). A number of extra‐pulmonary complications may also occur. These include Reye's syndrome in children (most commonly between two and 16 years of age), myocarditis, pericarditis and central nervous system (CNS) diseases. Again these include encephalitis, transverse myelitis and Guillain‐Barré syndrome (<a href="./references#CD002745-bbs2-0227" title="BarikS . New treatments for influenza. BMC Medicine2012;13(10):104. ">Barik 2012</a>; <a href="./references#CD002745-bbs2-0269" title="WiselkaM . Influenza: diagnosis, management and prophylaxis. BMJ1994;308:1341‐5. ">Wiselka 1994</a>). </p> <p>An interesting and clinically relevant aspect of pandemic and epidemic influenza that sets it apart from seasonal influenza is the induction of the so‐called cytokine storm, consisting of interleukin‐6, tumour necrosis factor and interferon‐g. Together, these proinflammatory cytokines cause systemic inflammatory response syndrome, leading to multi‐organ failure that includes airway destruction, vascular endothelial damage and plasma leakage (<a href="./references#CD002745-bbs2-0227" title="BarikS . New treatments for influenza. BMC Medicine2012;13(10):104. ">Barik 2012</a>; <a href="./references#CD002745-bbs2-0233" title="CheungCY , PoonLLM , LauAS , LukW , LauYL , ShortridgeKF , et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?. Lancet2002;360:1831‐7. ">Cheung 2002</a>) </p> </section> <section id="CD002745-sec-0025"> <h3 class="title" id="CD002745-sec-0025">Description of the intervention</h3> <p>Nowadays there are two main measures for the treatment and prophylaxis of influenza viruses: immunisation using influenza vaccines directly isolated from influenza A and B viruses and antiviral agents (<a href="./references#CD002745-bbs2-0234" title="DemicheliV , JeffersonT , RivettiD , DeeksJ . Prevention and early treatment of influenza in health adults. Vaccine2000;18:957‐1030. ">Demicheli 2000</a>; <a href="./references#CD002745-bbs2-0255" title="NoahDL , NoahJH . Adapting global influenza management strategies to address emerging viruses. American Journal of Physiology. Lung Cellular and Molecular Physiology2013;305:108‐17. ">Noah 2013</a>). Vaccination is the primary strategy for the prevention of influenza (<a href="./references#CD002745-bbs2-0226" title="AntonovaEN , RycroftCE , AmbroseCS , HeikkinenT , PrincipiN . Burden of paediatric influenza in Western Europe: a systematic review. BMC Public Health2012;12:968‐81. ">Antanova 2012</a>; <a href="./references#CD002745-bbs2-0096" title="HsuJ , SantessoN , MustafaR , BrozekJ , ChenYL , HopkinsJP , et al. Antivirals for treatment of influenza: a systematic review and meta‐analysis of observational studies. Annals of Internal Medicine2012;156:512‐24. ">Hsu 2012</a>). Nevertheless, there are a number of likely scenarios for which effective antiviral agents would be of utmost importance. For example, the available evidence on the safety, efficacy or effectiveness of influenza vaccines for people aged 65 years or older is of poor quality (<a href="./references#CD002745-bbs2-0246" title="JeffersonT , DiPietrantonjC , Al‐AnsaryLA , FerroniE , ThorningS , ThomasRE . Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews2010, Issue 2. [DOI: 10.1002/14651858.CD004876.pub3] ">Jefferson 2010</a>; <a href="./references#CD002745-bbs2-0261" title="ThomasRE , RussellM , LorenzettiD . Interventions to increase influenza vaccination rates of those 60 years and older in the community. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD005188.pub2] ">Thomas 2011</a>). Vaccination among the elderly may not be as effective as their immune systems are less responsive (<a href="./references#CD002745-bbs2-0258" title="SasakiS , SullivanM , NarvaezC , HolmesT , FurmanD , ZhengNY , et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine‐specific antibodies. Journal of Clinical Investigation2011;121(8):3109‐19. ">Sasaki 2011</a>). Influenza vaccines are efficacious in children older than two but little evidence is available for children under two (<a href="./references#CD002745-bbs2-0235" title="DemicheliV , JeffersonT , Al‐AnsaryLA , FerroniE , RivettiA , DiPietrantonjC . Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD004879.pub4] ">Demicheli 2012</a>). During any influenza season, antigenic drift in the virus may occur after formulation of the year's vaccine. The vaccine can therefore be less protective and outbreaks can more easily occur in high‐risk populations. In the course of a pandemic, vaccine supplies would be inadequate. Moreover, vaccine production by current methods cannot be carried out with the speed required to halt the progress of a new strain of influenza virus. Therefore, it is likely that vaccines would not be available for those infected by the first wave of the virus (<a href="./references#CD002745-bbs2-0241" title="HaydenFG . Pandemic influenza: is an antiviral response realistic?. Pediatric Infectious Disease Journal2004;23(Suppl):262‐9. ">Hayden 2004</a>). Additionally, in a study published in 2013, the author stated that vaccination‐only strategies were not cost‐effective for any pandemic scenario, saving few lives and incurring substantial vaccination costs (<a href="./references#CD002745-bbs2-0248" title="KelsoJK , HalderN , MilneGJ . Vaccination strategies for future influenza pandemics: a severity‐based cost effectiveness analysis. BMC Infectious Diseases2013;11:1‐13. ">Kelso 2013</a>). Vaccination, coupled with long duration social distancing, antiviral treatment and antiviral prophylaxis, was considered to be cost‐effective for moderate and extreme pandemics, as it can save lives while simultaneously reducing the total pandemic cost (<a href="./references#CD002745-bbs2-0248" title="KelsoJK , HalderN , MilneGJ . Vaccination strategies for future influenza pandemics: a severity‐based cost effectiveness analysis. BMC Infectious Diseases2013;11:1‐13. ">Kelso 2013</a>). Antiviral agents therefore form an important part of a rational approach to influenza management (<a href="./references#CD002745-bbs2-0248" title="KelsoJK , HalderN , MilneGJ . Vaccination strategies for future influenza pandemics: a severity‐based cost effectiveness analysis. BMC Infectious Diseases2013;11:1‐13. ">Kelso 2013</a>; <a href="./references#CD002745-bbs2-0252" title="MosconaA . Neuraminidase inhibitors for Influenza. New England Journal of Medicine2005;353:1363‐73. ">Moscona 2005</a>). </p> <p>Antiviral drugs for influenza are currently divided into two classes: M2 ion channel inhibitors and neuraminidase inhibitors. The first class includes amantadine and rimantadine and the latter zanamivir, oseltamivir, laninamivir (approved in Japan) and peramivir (approved in Japan and Korea) (<a href="./references#CD002745-bbs2-0227" title="BarikS . New treatments for influenza. BMC Medicine2012;13(10):104. ">Barik 2012</a>). M2 ion channel inhibitors affect ion channel activity through the cell membrane and are reported to be effective by interfering with the replication cycle of type A viruses (but not type B). The neuraminidase inhibitors interfere with the release of influenza virus progeny from infected host cells and are effective against influenza A and B (<a href="./references#CD002745-bbs2-0252" title="MosconaA . Neuraminidase inhibitors for Influenza. New England Journal of Medicine2005;353:1363‐73. ">Moscona 2005</a>). Both drug classes have shown partial effectiveness for the prevention and treatment of influenza A viruses, although neuraminidase inhibitors are less likely to promote the development of drug‐resistant influenza (<a href="./references#CD002745-bbs2-0252" title="MosconaA . Neuraminidase inhibitors for Influenza. New England Journal of Medicine2005;353:1363‐73. ">Moscona 2005</a>). </p> <p>Resistance to M2 inhibitors remained low until 2003 (<a href="./references#CD002745-bbs2-0230" title="BrightRA ,  MedinaMJ ,  XuX ,  Perez‐OronozG ,  WallisTR ,  DavisXM , et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet2005;366:1175‐81. ">Bright 2005</a>; <a href="./references#CD002745-bbs2-0272" title="ZieglerT , HemphillML , ZieglerML , Perez‐OronozG , KlimovAI , HampsonAW , et al. Low incidence of rimantadine resistance infield isolates of influenza A viruses. Journal of Infectious Diseases1999;4:935–9. ">Ziegler 1999</a>). An epidemiological study into resistance to amantadine carried out from 1991 to 1995 described a frequency of 1% (16/2017) of resistant variants among H1N1 and H3N2 viruses (<a href="./references#CD002745-bbs2-0272" title="ZieglerT , HemphillML , ZieglerML , Perez‐OronozG , KlimovAI , HampsonAW , et al. Low incidence of rimantadine resistance infield isolates of influenza A viruses. Journal of Infectious Diseases1999;4:935–9. ">Ziegler 1999</a>). However, there was a subsequently a dramatic increase in strains of influenza A (H3N2) with a specific mutation (Ser31Asn). An increase in resistance to amantadine was showed in communities located in Asia and North America (<a href="./references#CD002745-bbs2-0230" title="BrightRA ,  MedinaMJ ,  XuX ,  Perez‐OronozG ,  WallisTR ,  DavisXM , et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet2005;366:1175‐81. ">Bright 2005</a>; <a href="./references#CD002745-bbs2-0231" title="BrightRA , ShayDK , ShuB , CoxNJ , KlimovAI . Adamantane resistance among influenza A viruses isolated early during the2005‐2006 influenza season in the United States. JAMA2006;295:891‐4. ">Bright 2006</a>). This resistance in 70% to 90% of strains occurred despite the absence of sustained selective drug pressure (<a href="./references#CD002745-bbs2-0230" title="BrightRA ,  MedinaMJ ,  XuX ,  Perez‐OronozG ,  WallisTR ,  DavisXM , et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet2005;366:1175‐81. ">Bright 2005</a>; <a href="./references#CD002745-bbs2-0231" title="BrightRA , ShayDK , ShuB , CoxNJ , KlimovAI . Adamantane resistance among influenza A viruses isolated early during the2005‐2006 influenza season in the United States. JAMA2006;295:891‐4. ">Bright 2006</a>). </p> <p>During the 2005 to 2006 season, 16% of H1N1 and 91% of H3N2 viruses were resistant around the world. Although the estimate for the proportion of resistance in H1N1 viruses was very low, an analysis conducted in China showed that the frequency of resistant H1N1 viruses had greatly increased from 28% (8/29) in the 2004 to 2005 season to 72% (33/46) in the 2005 to 2006 season. Similar studies were conducted in other countries in the 2005 to 2006 season. The following frequencies of resistance were obtained: 45% (13/29) in Europe, 24% (4/17) in Taiwan and 33% (1/3) in Canada (<a href="./references#CD002745-bbs2-0236" title="DeydeVM ,  XuX ,  BrightRA ,  ShawM ,  SmithCB ,  ZhangY ,  etal . Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. Journal of Infectious Diseases2007;196(2):249‐57. ">Deyde 2007</a>). </p> <p>A global pandemic emerged in 2009, caused by a new influenza A strain (H1N1) (<a href="./references#CD002745-bbs2-0265" title="World Health Organization. Pandemic (H1N1) 2009 ‐ update 112. http://www.who.int/csr/don/2010_08_06/en/ 2010 (accessed 14 August 2011). ">WHO 2010a</a>). All influenza A (H1N1) viruses tested in WHO Collaborating Centres to date have been shown to be resistant to amantadine and rimantadine (<a href="./references#CD002745-bbs2-0267" title="World Health Organization. Global Influenza Surveillance and Response System (GISRS). http://www.who.int/influenza/gisrs_laboratory/en 2011 (accessed in 3 December 2011). ">WHO 2011</a>; <a href="./references#CD002745-bbs2-0268" title="World Health Organization. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses. http://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/en/ 2012 (accessed 20 August 2012). ">WHO 2012</a>). </p> <p>When an avian influenza A (H7N9) virus was detected as the cause of human infections in China, its susceptibility to antiviral drugs was assessed. The outbreak viruses carried the established adamantine resistance marker. Once again neuraminidase inhibitors remained the only licensed treatment option (<a href="./references#CD002745-bbs2-0250" title="LiQ , ZhouL , ZhouM , ChenZ , LiF , WuH , et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. New England Journal of Medicine2014;370:520‐32. ">Li 2014</a>). </p> <p>Influenza A resistance to amantadine and rimantadine has been frequently reported over the last few years and, as such, it may seem unnecessary to continue testing sensitivity to these drugs. However, patterns of sensitivity and resistance of influenza viruses to antiviral drugs may change over time and so we consider it necessary to continue monitoring sensitivity and resistance. </p> </section> <section id="CD002745-sec-0026"> <h3 class="title" id="CD002745-sec-0026">How the intervention might work</h3> <p>The use of amantadine and rimantadine for the treatment and prevention of influenza A in adults has already been the topic of a review (<a href="./references#CD002745-bbs2-0245" title="JeffersonT , DemicheliV , DiPietrantonjC , RivettiD . Amantadine and rimantadine for influenza A in adults. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD001169.pub3] ">Jefferson 2006b</a>). The results of that review confirmed that amantadine and rimantadine had a comparable efficacy and effectiveness in the treatment of influenza A in healthy adults, although their effectiveness in interrupting transmission was probably low. As previous pandemics proved to be susceptible to this class of drugs, it seems reasonable to review the evidence for amantadine and rimantadine for treating and preventing influenza A in children and the elderly (<a href="./references#CD002745-bbs2-0243" title="HaydenFG . Antiviral resistance in influenza viruses ‐ implications for management and pandemic response. New England Journal of Medicine2006;354(8):785‐8. ">Hayden 2006b</a>). </p> </section> <section id="CD002745-sec-0027"> <h3 class="title" id="CD002745-sec-0027">Why it is important to do this review</h3> <p>Although the disease occurs in all age groups (<a href="./references#CD002745-bbs2-0256" title="Pineda SolasA , Bernaola IturbeE , Martinon‐TorresF , Baca CotsM , DeJuan MartinF , Gomez CampderaJA , et al. Recommendations of the Vaccine Advisory Committee of the Spanish Association of Pediatrics: influenza vaccination campaign 2006‐2007. Anales de Pediatría2006;65(3):252‐5. ">Pineda Solas 2006</a>), the risks of complications, hospitalisations and deaths from influenza are higher among three groups of people: 1) persons older than 65 years; 2) young children; and 3) persons of any age who have medical conditions that place them at increased risk. Rates of infection are highest amongst children and they are also one of the most important links for transmission (<a href="./references#CD002745-bbs2-0237" title="DolinR . Influenza‐interpandemic as well as pandemic disease. New England Journal of Medicine2005;353(24):2535‐7. ">Dolin 2005</a>). </p> <p>Pandemics occur when influenza spreads globally, infecting 20% to 40% of the world's population in one year. This results in as many as 10 million deaths (<a href="./references#CD002745-bbs2-0263" title="World Health Organization. Influenza. Geneva, World Health Organization, 2003 (Fact Sheet No. 211). http://www.who.int/mediacentre/factsheets/fs211/en/print.html 2003 (accessed 20 October 2007). ">WHO 2003</a>). They usually arise in China, where pigs, ducks and humans live in close proximity to each other, and spread westward to the rest of Asia, Europe and the Americas (<a href="./references#CD002745-bbs2-0229" title="BonnD . Spared an influenza pandemic for another year?. Lancet1997;349(9044):36. ">Bonn 1997</a>). In the past 110 years there have been five pandemics caused by different influenza A viral subtypes. The Spanish influenza pandemic (1918 to 1919) is considered to have caused an estimated 40 million deaths worldwide. Most years, typical influenza epidemics infect 5% to 20% of the population and result in anywhere between 250,000 and 500,000 deaths, according to the World Health Organization (WHO), although other estimates accounting for deaths due to complications of influenza are as high as 1 million to 1.5 million. </p> <p>In 2009, a new influenza A strain (H1N1) caused a global pandemic. According to the WHO, as of 24 January 2010, more than 214 countries and overseas territories had reported laboratory‐confirmed cases of pandemic influenza H1N1, resulting in at least 18,449 deaths (<a href="./references#CD002745-bbs2-0265" title="World Health Organization. Pandemic (H1N1) 2009 ‐ update 112. http://www.who.int/csr/don/2010_08_06/en/ 2010 (accessed 14 August 2011). ">WHO 2010a</a>). </p> <p>In an earlier version of a Cochrane review in adults, the review authors stated that neuraminidase inhibitors were effective in reducing symptoms and complications, however there are now doubts about their effectiveness against complications (<a href="./references#CD002745-bbs2-0247" title="JeffersonT , JonesMA , DoshiP , DelMarCB , HamaR , ThompsonMJ , et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD008965.pub4] ">Jefferson 2014</a>). </p> <p>In a Cochrane review published in 2007, the review authors concluded that oseltamivir may be considered for the treatment of children aged one to 12 years with influenza infection (<a href="./references#CD002745-bbs2-0145" title="MathesonNJ , HarndenAR , PereraR , SheikhA , Symmonds‐AbrahamsM . Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD002744.pub2] ">Matheson 2007</a>). This antiviral is likely to shorten the duration of symptoms, hasten the return to normal activities and reduce the incidence of secondary complications. Nevertheless, the review authors also concluded that more data were needed to clarify the benefits of neuraminidase inhibitors for the treatment of influenza in asthmatic children (including addressing the potential confounder of prior vaccination). </p> <p>Nowadays, neuraminidase inhibitors are used as a prescription drug for patients suffering from influenza on the recommendation of the WHO (<a href="./references#CD002745-bbs2-0266" title="World Health Organization. Essential medicines selection. Unedited report of the supplementary meeting of the expert committee on the selection and use of essential medicines. http://www.who.int/selection_medicines/committees/expert/emergency_session/unedited_Emergency_report.pdf 2010 (accessed 14 August 2011). ">WHO 2010b</a>). Governments have spent billions of dollars stockpiling neuraminidase inhibitors as a public health measure (<a href="./references#CD002745-bbs2-0266" title="World Health Organization. Essential medicines selection. Unedited report of the supplementary meeting of the expert committee on the selection and use of essential medicines. http://www.who.int/selection_medicines/committees/expert/emergency_session/unedited_Emergency_report.pdf 2010 (accessed 14 August 2011). ">WHO 2010b</a>). In previous pandemics, the influenza A virus was susceptible to amantadine and rimantadine. Therefore, these antivirals could be a less expensive alternative in the management of influenza if the circulating strain proves to be susceptible to amantadine and rimantadine (<a href="./references#CD002745-bbs2-0243" title="HaydenFG . Antiviral resistance in influenza viruses ‐ implications for management and pandemic response. New England Journal of Medicine2006;354(8):785‐8. ">Hayden 2006b</a>). However, we should emphasise the resistance patterns of the pandemic viruses in 2009. All influenza A (H1N1) viruses tested in WHO Collaborating Centres to date were sensitive to zanamivir and all were resistant to amantadine and rimantadine (<a href="./references#CD002745-bbs2-0267" title="World Health Organization. Global Influenza Surveillance and Response System (GISRS). http://www.who.int/influenza/gisrs_laboratory/en 2011 (accessed in 3 December 2011). ">WHO 2011</a>). </p> <p>These facts reinforce the importance of conducting and maintaining reviews of a variety of treatments, especially less expensive ones, for the treatment and prevention of influenza. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002745-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002745-sec-0028"></div> <p>To assess the effectiveness and safety of amantadine and rimantadine in preventing, treating and shortening the duration of influenza A in children and the elderly. </p> <p>We tested the following hypotheses in comparisons between groups intended for amantadine or rimantadine prophylaxis or treatment compared with control groups: </p> <p> <ol id="CD002745-list-0001"> <li> <p>there is no difference in the number of cases of influenza A or in the duration of influenza symptoms; and </p> </li> <li> <p>there is no difference in the number of adverse effects.</p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002745-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002745-sec-0029"></div> <section id="CD002745-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002745-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) and quasi‐RCTs comparing amantadine or rimantadine, or both, with placebo, control drugs, different doses or schedules of amantadine or rimantadine, or both, or no intervention, in children and the elderly. </p> </section> <section id="CD002745-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included studies where at least 75% of the population was up to 19 years of age, or 65 years of age or older. We also included trials with a wider age range where data by age subgroups were available. </p> </section> <section id="CD002745-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Comparisons of amantadine or rimantadine, or both, to placebo, control drugs, other antivirals, no interventions or different doses of amantadine or rimantadine, or both, as prophylaxis and/or treatment for influenza A. </p> </section> <section id="CD002745-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD002745-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD002745-list-0002"> <li> <p>Response to treatment (measured as cases on the specified day of treatment): fever on day three of treatment, cough on day seven of treatment, malaise on day six of treatment and conjunctivitis and eye symptoms on day five of treatment. </p> </li> <li> <p>Cases of influenza, studied in all prophylaxis comparisons, including those in which two antivirals (rimantadine and zanamivir) (<a href="./references#CD002745-bbs2-0005" title="GravensteinS , DrinkaP , OsterweilD , SchillingM , KrauseP , ElliotM , et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long‐term care population. Journal of the American Medical Directors Association2005;6:359‐66. ">Gravenstein 2005</a>; <a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a>), and two different doses of rimantadine were compared (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>). </p> </li> <li> <p>Cases of side effects in children: diarrhoea, exanthema, malaise, muscular limb pain, headache, dyspnoea, dizziness, stimulation/insomnia, nausea, vomiting, arrhythmia, gastrointestinal (GI) symptoms, CNS symptoms, change in behaviour, hyperactivity and tinnitus. </p> </li> <li> <p>Cases of side effects in the elderly: headache, dizziness, stimulation/insomnia, nausea, vomiting, anxiety, confusion, fatigue, depression, impaired concentration, loss of appetite, rash or allergic reaction, seizures or clonic twitching, dry mouth, insomnia or sleeplessness, body weakness and debility. </p> </li> </ol> </p> <p>We used dichotomous outcomes for all the comparisons.</p> </section> <section id="CD002745-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p>The following outcomes appeared in the protocol but in the end we did not consider them in the analysis, as they were not reported in the included trials: patients' well‐being, admission to hospital, general practitioner (GP) visits and other drugs used. We could not analyse deaths. Although cited by <a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>, they were included among other causes of withdrawal. </p> </section> </section> </section> <section id="CD002745-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002745-sec-0038"> <h4 class="title">Electronic searches</h4> <p>For this 2014 update we searched the Cochrane Central Register of Controlled Trials (CENTRAL 2014, Issue 9) (accessed 7 October 2014), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (June 2011 to September week 4, 2014) and EMBASE (June 2011 to October 2014). </p> <p>The search strategy for MEDLINE and CENTRAL is described in <a href="./appendices#CD002745-sec-0097">Appendix 1</a>. See <a href="./appendices#CD002745-sec-0098">Appendix 2</a> for the EMBASE search strategy. We imposed no language or publication restrictions. We used the same search strategy for our previous update in 2011, searching the Cochrane Central Register of Controlled Trials (CENTRAL 2011, Issue 2), MEDLINE (July 2007 to June week 3, 2011) and EMBASE.com (July 2007 to June 2011). Details of the review's initial search are in <a href="./appendices#CD002745-sec-0099">Appendix 3</a>. </p> </section> <section id="CD002745-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We searched the trials registries WHO International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov for completed and ongoing trials (latest search 7 October 2014). We screened bibliographies of retrieved articles and reviews in order to identify further trials. We contacted pharmaceutical companies and researchers active in the field for unpublished trials. </p> </section> </section> <section id="CD002745-sec-0040"> <h3 class="title" id="CD002745-sec-0040">Data collection and analysis</h3> <section id="CD002745-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MG and MS) independently applied the selection criteria to all retrieved articles and extracted data using a data extraction form, specifically designed for this review. We resolved disagreements by consensus. We appointed one review author (AC) as arbitrator when necessary. </p> <p>We entered extracted data into <a href="./references#CD002745-bbs2-0257" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>. Combination of data was dependent on population characteristics and outcomes studied. </p> </section> <section id="CD002745-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MG, MS) independently read the retrieved trials and applied the selection criteria. We independently extracted and reviewed data using the data collection form previously developed for this review. Two review authors (MG, MS) resolved disagreements on the quality of the trials by consensus. We appointed a third author (AC) as arbitrator if necessary. </p> <p>We emailed the authors of primary studies when the complete information sought was not available in study reports. We obtained authors' contact details from the study reports, other recent publications, university directories or by searching the world wide web. We recorded the following data. </p> <p> <ol id="CD002745-list-0003"> <li> <p>Setting: hospital, emergency, offices or clinics, primary health care, nursing homes, communities, prisons, military personnel, nursery or day care. </p> </li> <li> <p>Participants: criteria for patients to join the trial, age, gender, diagnostic criteria and co‐morbid conditions. </p> </li> <li> <p>Interventions: placebo, other than amantadine and rimantadine antiviral controls, comparing different doses or schedules of amantadine and/or rimantadine or no intervention. </p> </li> <li> <p>Outcome measures: global symptom improvements, relief, death, cases of influenza, malaise, fever, nausea, arthralgia, rash, headache, systemic and serious side effects, well‐being, admission to hospital, GP visits, other drugs used, cough, coryza, sore throat, hoarseness, vomiting, abdominal pain, insomnia, irritability, behaviour changes and anorexia. </p> </li> <li> <p>Adverse effects: dry mouth, drowsiness/fatigue, constipation, urinary retention, sweating, headache, diarrhoea, palpitations, irritability, blurred vision, dizziness/light headedness and nausea/vomiting and any other systemic and serious side effects. </p> </li> </ol> </p> </section> <section id="CD002745-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MG, MS) independently screened trial quality. We resolved disagreements by discussion. We appointed a third author (AC) to act as arbitrator when necessary. We used the criteria recommended by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to assess the risk of bias (<a href="./references#CD002745-bbs2-0244" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We developed a form and populated it to assess the risk of bias, based on a Cochrane review (<a href="./references#CD002745-bbs2-0225" title="Ahovuo‐SalorantaA , RautakorpiU‐M , BorisenkoOV , LiiraH , Williams JrJW , MäkeläM . Antibiotics for acute maxillary sinusitis in adults. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD000243.pub3] ">Ahovuo‐Saloranta 2014</a>). We indicated if the risk of bias was low, high , or even unclear, indicating either a lack of information or uncertainty over the potential for bias. </p> <p><b>1. Sequence generation:</b> was the method used to generate the allocation sequence appropriate to produce comparable groups? We considered that the risk of bias was low if the authors described a random component in the sequence generation process (for example, a random number table, a computerised random number table, coin tossing, shuffling cards or envelopes, throwing dice, drawing of lots). If there was no or insufficient information about the sequence generation process, we marked this domain 'unclear'. We considered that there was a high risk of bias if the sequence was generated by: 1) odds and evens or date of birth; 2) some rule based on date (or day) of admission; 3) some rule based on hospital or clinic record number. </p> <p><b>2. Allocation sequence concealment: </b>was the method used to conceal the allocation sequence appropriate to prevent the allocation being known in advance of, or during, enrolment? We marked this domain 'low risk' of bias if the trial authors described adequate concealment (for example, by means of either central allocation, sequentially numbered drug containers of identical appearance, or sequentially numbered, opaque, sealed envelopes) and 'high risk' of bias if: 1) inadequate concealment was documented; 2) allocation concealment was not used (for example, using either an open random allocation schedule, assignment envelopes without appropriate safeguards, alternation or rotation, date of birth or case record number). We marked this domain 'unclear' if: 1) insufficient information about allocation concealment was provided; 2) the information was unclearly reported. </p> <p><b>3. Blinding of participants and personnel:</b> were adequate measures used to blind study participants and personnel from knowing which intervention a participant received? We marked this domain 'low risk' of blinding if the RCT authors stated that: 1) there was no blinding; 2) there was incomplete blinding but the review authors judged that the outcome was not likely to be influenced by said incomplete blinding; 3) blinding of participants and key study personnel was ensured and it is unlikely that the blinding could have been broken. We marked this domain 'high risk' of bias, if the RCT authors described: 1) no blinding; 2) incomplete blinding and the outcome was likely to be influenced by said incomplete blinding; 3) blinding of key study participants and personnel but it was likely that the blinding could have been broken. We marked this domain 'unclear' if there was insufficient information or if the study did not address this outcome. </p> <p><b>4. Blinding of outcome assessment:</b> were adequate measures used to blind outcome assessors from knowing which intervention a participant received? We marked this domain 'low risk' of bias if there was: 1) no blinding of outcome assessment but the review authors judged that the outcome measurement was not likely to be influenced by lack of blinding; 2) blinding of outcome assessors was ensured and it is unlikely that the blinding could have been broken. We marked this domain 'high risk' of bias, if: 1) no blinding of outcome assessment was stated and the outcome measurement was likely to be influenced by lack of blinding; 2) there was blinding of outcome assessors but it was likely that the blinding could have been broken. We marked this domain 'unclear' if there was insufficient information or if the study did not address this outcome. </p> <p><b>5. Incomplete outcome data</b> describes how complete the data were for the clinical outcomes. Were dropout rates and reasons for withdrawals reported? Were missing data imputed appropriately? We marked this domain 'low risk' of bias if the RCT authors stated that: 1) there were no missing outcome data; 2) the reasons for missing outcome data were unlikely to be related to true outcome: 3) missing outcome data balanced out across intervention groups, with similar reasons for missing data across said groups; 4) the proportion of missing outcomes compared with the observed event risk was not enough to have a clinically relevant impact on the intervention effect estimate; 5) missing data were imputed using appropriate methods. We marked this domain 'high risk' of bias, representing a high risk of attrition bias, if: 1) the reason for missing outcome data was likely to be related to true outcome, with either an imbalance in numbers or reasons for missing data across intervention groups; 2) the proportion of missing outcomes compared with the observed event risk was enough to induce clinically relevant bias in the intervention effect estimate; 3) 'as‐treated' analysis was done with substantial departure of the intervention received from that assigned at randomisation; 4) there was potentially inappropriate application of simple imputation. 'unclear risk of bias' was the expected classification of studies in which there was insufficient reporting of attrition/exclusions to permit the classification of 'low risk' or 'high risk' (e.g. number of randomised patients not stated, no reasons for missing data provided), or if the study did not address this outcome. </p> <p>We completed a 'Risk of bias' table for each included study (see 'Risk of bias' tables in the <a href="./references#CD002745-sec-0111" title="">Characteristics of included studies</a> table).   </p> </section> <section id="CD002745-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated risk ratios (RRs) and 95% confidence intervals (CI) for each study as all the outcomes studied were dichotomous. We tested for heterogeneity for each outcome. </p> </section> <section id="CD002745-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>In the <a href="./references#CD002745-bbs2-0005" title="GravensteinS , DrinkaP , OsterweilD , SchillingM , KrauseP , ElliotM , et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long‐term care population. Journal of the American Medical Directors Association2005;6:359‐66. ">Gravenstein 2005</a> trial, the author stated that the study was conducted over three winter seasons and that some participants were randomised more than once. Taking into account that influenza was the outcome of interest and that in each season different influenza viruses emerge, participants that had acquired the infection in one of the seasons could not be considered to be immunologically resistant to influenza in the next season. Consequently, we decided to include all participants described by the trial authors, as this does not seem to produce bias. </p> <p>In the <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a> and <a href="./references#CD002745-bbs2-0002" title="CloverRD , WarnerJL , BeckerL , DavisA . Effect of rimantadine on the immune response to influenza A infections. Journal of Medical Virology1991;34(1):68‐73. [MEDLINE: 1885945] ">Clover 1991</a> studies, eligible family members were randomly assigned as a block to study rimantadine in the prevention of influenza. For the purpose of this review, we selected the children as the subgroup of interest. It could be expected that children from families in the intervention group could be more protected from influenza than children in the control group. Nevertheless, no effect was shown in either of the three trials selected for this comparison (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0002" title="CloverRD , WarnerJL , BeckerL , DavisA . Effect of rimantadine on the immune response to influenza A infections. Journal of Medical Virology1991;34(1):68‐73. [MEDLINE: 1885945] ">Clover 1991</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>). </p> </section> <section id="CD002745-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the trial authors to request missing data when data were not clearly provided. We analysed the available data, taking into account the relatively small number and randomness of missing data. </p> </section> <section id="CD002745-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We stored the data extracted from primary studies in the Review Manager software (<a href="./references#CD002745-bbs2-0257" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). All the outcomes we studied were dichotomous.<br/> We determined whether there were sufficiently homogeneous data to combine when there were two or more selected studies for a given comparison. We grouped the previously selected articles according to the characteristics of interventions, outcomes and populations studied. We had to take into account that pooled studies may still differ from each other even though the initial application of this filter was supposed to reduce the possibility of heterogeneity. </p> <p>We initially inspected forest plots generated by <a href="./references#CD002745-bbs2-0257" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a> to evaluate the possibility of heterogeneity between studies. We applied the Cochrane test for homogeneity. With this aim we set a P value of 0.1 as the limit for considering the existence of heterogeneity (<a href="./references#CD002745-bbs2-0232" title="Centro CochraneIberoamericano . Introduction to systematic reviews [Curso de introducción a las revisiones sistemáticas]. http://www.cochrane.es/ 2006 (accessed 12 January 2007). ">CCI 2006</a>). We also applied the I<sup>2</sup> statistic to quantify heterogeneity among the trials and to verify the impact on the meta‐analysis, considering that some clinical and methodological diversity always occurs in a meta‐analysis. We considered values above 50% to be representative of significant heterogeneity (<a href="./references#CD002745-bbs2-0244" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), and we explored the causes. We used the subgroup analysis of participants or a subgroup analysis of the studies selected for each comparison when the heterogeneity was relevant to the outcome of the meta‐analysis. </p> </section> <section id="CD002745-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We considered assessment of reporting biases to be at risk because of the small number of studies selected for each comparison. Nevertheless, we relied on extensive research and carefully examined the references of the studies found in the search results to avoid reporting biases. We analysed all trials that met the inclusion criteria, independently of the journal's impact factor, the year of publication, the language in which the article was written and the origin of both author and publication. The use of these criteria can be confirmed by checking the lists of included and excluded studies. </p> </section> <section id="CD002745-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We used the risk ratio (RR) and respective 95% confidence interval (CI) as a summary measure to combine data. We calculated the necessary number of patients to be treated for an individual to benefit from treatment with respect to an outcome (number needed to treat to benefit (NNTB)) and its 95% CI, when a statistical difference was found. We estimated the occurrence of an event in the population, or absolute risk (baseline risk) based on the rate of event occurrence in controls (control group rate (CGR)) for this calculation. </p> <p>We used the random‐effects model to calculate the summary measure, with the assumption that although the articles could have addressed somewhat different issues, they could be viewed as a family of studies on similar questions. We considered that the articles were a random sample of all studies that addressed the questions we were interested in. Therefore, even considering the possibility of failure of the statistical tests of homogeneity, the combination of similar studies would still be a reasonable procedure. Although it is impossible to state if the articles were really a random sample of all research on an issue, this model is more realistic and less prone to overestimate accuracy (<a href="./references#CD002745-bbs2-0239" title="FletcherRH , FletcherSW . Epidemiologia Clínica: Elementos Essenciais. 4th Edition. Porto Alegre, Brazil: Artmed, 2006. ">Fletcher 2006</a>). </p> </section> <section id="CD002745-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We pre‐specified some subgroup analyses to investigate heterogeneity. We planned to take into account the drugs used for control and treatment, their doses and the previous use of anti‐influenza vaccine(s). However, we stress that the subgroup analysis does not take into account the randomisation processes, so these results must be considered with caution. </p> </section> <section id="CD002745-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analyses to explore heterogeneity. We conducted subgroup analyses for subsets of participants. We had planned to analyse rimantadine and amantadine separately and together. However, when we identified the use of different antivirals being used as a control, we performed a subgroup analysis. We separated the trials in which the comparison was made using different antiviral medications from those in which the control was made with placebo or other drugs. We also carried out subgroup analyses for subsets of immunised and non‐immunised participants, as well as according to the dosages of antivirals tested in the trials. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002745-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002745-sec-0052"></div> <section id="CD002745-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD002745-sec-0054"> <h4 class="title">Results of the search</h4> <p>We retrieved a total of 33 records in this updated search. Out of a total of 205 abstracts, titles and studies that we retrieved through all the searches, 195 were written in English, three in Russian, two in Czech, three in German, one in French and one in Japanese. We discarded 129 studies. We assessed the remaining 78 articles in detail. It was necessary to contact 46 trial authors to verify that their studies met our selection criteria. We included 12 trials in this review. All of them are published trials and are described in the <a href="./references#CD002745-sec-0111" title="">Characteristics of included studies</a> table. We added another 38 trials in 2011 when we updated this review; we excluded all of them and our conclusions remain unchanged. </p> <p>We did not identify any new trials for inclusion in this 2014 update. We excluded 20 new trials (<a href="./references#CD002745-bbs2-0017" title="AntonA , PumarolaT . Influenza in immunocompromised patients: Considerations for therapy. Future Virology2011;6:855‐68. ">Anton 2011</a>; <a href="./references#CD002745-bbs2-0021" title="AtieeG , LasseterK , BaughmanS , McCulloughA , CollisP , HollisterA , et al. Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans. Journal of Clinical Pharmacology2012;52:1410‐9. ">Atiee 2012</a>; <a href="./references#CD002745-bbs2-0023" title="BacosiM , RussoF , D'InnocenzoS , SantolamazzaM , MiglioresiL , UrsittiA , et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatology Research2002;22:231‐9. ">Bacosi 2002</a>; <a href="./references#CD002745-bbs2-0041" title="Cayley JrWE . Are neuraminidase inhibitors effective for preventing and treating influenza in healthy adults and children?. American Family Physician2012;86:624‐6. ">Cayley 2012</a>; <a href="./references#CD002745-bbs2-0047" title="ChengVCC , ToKKW , TseH , HungIFN , YuenKY . Two years after pandemic influenza A/2009/H1N1: What have we learned?. Clinical Microbiology Reviews2012;25:223‐63. ">Cheng 2012</a>; <a href="./references#CD002745-bbs2-0058" title="DeVincenzoJP . The promise, pitfalls and progress of RNA‐interference‐based antiviral therapy for respiratory viruses. Antiviral Therapy2012;17:213‐25. ">De Vincenzo 2012</a>; <a href="./references#CD002745-bbs2-0065" title="EscuretV , CornuC , BoutitieF , EnoufV , MosnierA , Bouscambert‐DuchampM , et al. Oseltamivir‐zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A (H1N1) virus infections. Antiviral Research2012;96:130‐7. ">Escuret 2012</a>; <a href="./references#CD002745-bbs2-0076" title="GatwoodJ , MeltzerMI , MessonnierM , Ortega‐SanchezIR , BalkrishnanR , ProsserLA . Seasonal influenza vaccination of healthy working‐age adults: a review of economic evaluations. Drugs2012;72:35‐48. ">Gatwood 2012</a>; <a href="./references#CD002745-bbs2-0091" title="HaydenFG . Experimental human influenza: Observations from studies of influenza antivirals. Antiviral Therapy2012;17:133‐41. ">Hayden 2012</a>; <a href="./references#CD002745-bbs2-0096" title="HsuJ , SantessoN , MustafaR , BrozekJ , ChenYL , HopkinsJP , et al. Antivirals for treatment of influenza: a systematic review and meta‐analysis of observational studies. Annals of Internal Medicine2012;156:512‐24. ">Hsu 2012</a>; <a href="./references#CD002745-bbs2-0103" title="IsonMG . Clinical use of approved influenza antivirals: therapy and prophylaxis. Influenza &amp; Other Respiratory Viruses2013;7(Suppl 1):7‐13. ">Ison 2013</a>; <a href="./references#CD002745-bbs2-0107" title="JiangL , DengL , WuT . Chinese medicinal herbs for influenza. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD004559.pub4] ">Jiang 2013</a>; <a href="./references#CD002745-bbs2-0135" title="Lopez‐MedranoF , Carmen FarinasM , PayerasA , PachonJ . Antiviral treatment and vaccination for influenza A (H1N1) pdm09 virus: lessons learned from the pandemic. Enfermedades Infecciosas y Microbiologia Clinica2012;30:49‐53. ">Lopez‐Medrano 2012</a>; <a href="./references#CD002745-bbs2-0136" title="LouieJK , YangS , YenC , AcostaM , SchechterR , UyekiTM . Use of intravenous peramivir for treatment of severe influenza A (H1N1) pdm09. PloS One2012;7(6):e40261. ">Louie 2012</a>; <a href="./references#CD002745-bbs2-0150" title="MichielsB , vanPuyenbroeckK , VerhoevenV , VermeireE , CoenenS . The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PloS One2013;8(4):e60348. ">Michiels 2013</a>; <a href="./references#CD002745-bbs2-0179" title="SampaioC , BronzovaJ , HauserRA , LangAE , RascolO , van deWitteSV , et al. Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials. Movement Disorders2011;26:1464‐76. ">Sampaio 2011</a>; <a href="./references#CD002745-bbs2-0180" title="SantessoN , HsuJ , MustafaR , BrozekJ , ChenYL , HopkinsJP , et al. Antivirals for influenza: A summary of a systematic review and meta‐analysis of observational studies. Influenza and other Respiratory Viruses2013;7:76‐81. ">Santesso 2013</a>; <a href="./references#CD002745-bbs2-0188" title="ShahDP , GhantojiSS , MulanovichVE , Ariza‐HerediaEJ , ChemalyRF . Management of respiratory viral infections in hematopoietic cell transplant recipients. American Journal of Blood Research2012;2:203‐18. ">Shah 2012</a>; <a href="./references#CD002745-bbs2-0192" title="SingerB , RossAP , TobiasK . Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis. International Journal of Clinical Practice2011;65:887‐95. ">Singer 2011</a>; <a href="./references#CD002745-bbs2-0223" title="YuenC , ChanY , TambyahPA . Preflucel (registered trademark): a Vero‐cell culture‐derived trivalent influenza vaccine. Expert Review of Vaccines2012;11:759‐73. ">Yuen 2012</a>). </p> </section> <section id="CD002745-sec-0055"> <h4 class="title">Included studies</h4> <p>The 12 included studies were all randomised trials (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0002" title="CloverRD , WarnerJL , BeckerL , DavisA . Effect of rimantadine on the immune response to influenza A infections. Journal of Medical Virology1991;34(1):68‐73. [MEDLINE: 1885945] ">Clover 1991</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>; <a href="./references#CD002745-bbs2-0004" title="FinkleaJF , HennessyAV , DavenportFM . A field trial of amantadine prophylaxis in naturally‐occurring acute respiratory illness. American Journal of Epidemiology1967;85:403‐12. [5337715] ">Finklea 1967</a>; <a href="./references#CD002745-bbs2-0005" title="GravensteinS , DrinkaP , OsterweilD , SchillingM , KrauseP , ElliotM , et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long‐term care population. Journal of the American Medical Directors Association2005;6:359‐66. ">Gravenstein 2005</a>; <a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>; <a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>; <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a>; <a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>; <a href="./references#CD002745-bbs2-0011" title="PaylerDK , PurdhamPA . Influenza A prophylaxis with amantadine in a boarding school. Lancet1984;1(8375):502‐4. ">Payler 1984</a>; <a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a>); 11 were blinded and one was unblinded (<a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a>). The methods of randomisation and the follow‐up period were poorly described in all studies, although we could estimate that follow‐up ranged from eight to 120 days. We classified the included trials into two major groups: those conducted in children and those in the elderly. </p> <section id="CD002745-sec-0056"> <h5 class="title">Trials in children</h5> <p>Eight selected studies looked at the following.</p> <p> <ol id="CD002745-list-0004"> <li> <p>Treatment with amantadine (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>; <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a>) and rimantadine (<a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>). </p> </li> <li> <p>Prophylaxis with amantadine (<a href="./references#CD002745-bbs2-0004" title="FinkleaJF , HennessyAV , DavenportFM . A field trial of amantadine prophylaxis in naturally‐occurring acute respiratory illness. American Journal of Epidemiology1967;85:403‐12. [5337715] ">Finklea 1967</a>; <a href="./references#CD002745-bbs2-0011" title="PaylerDK , PurdhamPA . Influenza A prophylaxis with amantadine in a boarding school. Lancet1984;1(8375):502‐4. ">Payler 1984</a>) and rimantadine (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0002" title="CloverRD , WarnerJL , BeckerL , DavisA . Effect of rimantadine on the immune response to influenza A infections. Journal of Medical Virology1991;34(1):68‐73. [MEDLINE: 1885945] ">Clover 1991</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>). </p> </li> <li> <p>Adverse effects due to amantadine (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>; <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a>) and rimantadine (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>; <a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>). </p> </li> </ol> </p> <p>For treatment trials and the outcome fever on day three of treatment, the amantadine arm size was 51 and the control arm size was 53 children (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>; <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a>). The rimantadine arm size was 37 and the control arm size was 32 children (<a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>). For the other outcomes, cough on day seven, malaise on day six and eye symptoms on day five, we selected just one trial (<a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>). The rimantadine arm size was 37 and control arm size was 32 children for each of these outcomes. </p> <p>In the five prophylaxis trials, we applied wider age ranges for children than the definition stated in the protocol (participants up to 16 years of age). These trials included older participants who were adolescents by the WHO definition (<a href="./references#CD002745-bbs2-0264" title="World Health Organization. Child and adolescent health and development. http://www.who.int/child‐adolescent‐health/over.htm 2007 (20 accessed January 2007). ">WHO 2007</a>). Data regarding the proportion of the subgroup which strictly fulfilled the age criterion were not available in these studies or by contacting the trial authors. The respective age ranges were one to 17 years (<a href="./references#CD002745-bbs2-0002" title="CloverRD , WarnerJL , BeckerL , DavisA . Effect of rimantadine on the immune response to influenza A infections. Journal of Medical Virology1991;34(1):68‐73. [MEDLINE: 1885945] ">Clover 1991</a>), 13 to 19 years (<a href="./references#CD002745-bbs2-0011" title="PaylerDK , PurdhamPA . Influenza A prophylaxis with amantadine in a boarding school. Lancet1984;1(8375):502‐4. ">Payler 1984</a>), one to 18 years (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>), and eight to 19 years of age (<a href="./references#CD002745-bbs2-0004" title="FinkleaJF , HennessyAV , DavenportFM . A field trial of amantadine prophylaxis in naturally‐occurring acute respiratory illness. American Journal of Epidemiology1967;85:403‐12. [5337715] ">Finklea 1967</a>). The amantadine arm size was 368 (<a href="./references#CD002745-bbs2-0004" title="FinkleaJF , HennessyAV , DavenportFM . A field trial of amantadine prophylaxis in naturally‐occurring acute respiratory illness. American Journal of Epidemiology1967;85:403‐12. [5337715] ">Finklea 1967</a> (104); <a href="./references#CD002745-bbs2-0011" title="PaylerDK , PurdhamPA . Influenza A prophylaxis with amantadine in a boarding school. Lancet1984;1(8375):502‐4. ">Payler 1984</a> (264)) and the control arm size was 373 children (<a href="./references#CD002745-bbs2-0004" title="FinkleaJF , HennessyAV , DavenportFM . A field trial of amantadine prophylaxis in naturally‐occurring acute respiratory illness. American Journal of Epidemiology1967;85:403‐12. [5337715] ">Finklea 1967</a> (133); <a href="./references#CD002745-bbs2-0011" title="PaylerDK , PurdhamPA . Influenza A prophylaxis with amantadine in a boarding school. Lancet1984;1(8375):502‐4. ">Payler 1984</a> (240)). The rimantadine arm size was 84 (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a> (35); <a href="./references#CD002745-bbs2-0002" title="CloverRD , WarnerJL , BeckerL , DavisA . Effect of rimantadine on the immune response to influenza A infections. Journal of Medical Virology1991;34(1):68‐73. [MEDLINE: 1885945] ">Clover 1991</a> (22); <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a> (27)) and the control arm size was 94 participants (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a> (41); <a href="./references#CD002745-bbs2-0002" title="CloverRD , WarnerJL , BeckerL , DavisA . Effect of rimantadine on the immune response to influenza A infections. Journal of Medical Virology1991;34(1):68‐73. [MEDLINE: 1885945] ">Clover 1991</a> (24); <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a> (29)). </p> <p>Reported adverse effects of amantadine included exanthema, malaise, muscular limb pain, headache, arrhythmia and stimulation/insomnia. The antiviral arm size was 264 children (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a> (75); <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a> (189)) and the control arm size was 335 (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a> (84); <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a> (251)). </p> <p>A reported adverse effect of amantadine was dyspnoea. The antiviral arm size was 75 and the control arm size was 84 children (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>). For the adverse effects of hyperreactivity and tinnitus the rimantadine arm size was 27 and the control arm size was 29 children (<a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>). </p> <p>Nausea/vomiting, diarrhoea and dizziness were described as possible adverse effects for both antivirals. For nausea/vomiting, the amantadine arm size was 264 children (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a> (75); <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a> (189)) and the control arm size was 335 (<a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a> (251); <a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a> (84)). The rimantadine arm size was 38 (<a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a> (1); <a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a> (37)) and the control arm size was 61 (<a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a> (29); <a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a> (32)). </p> <p>For diarrhoea and dizziness the amantadine arm size was 264 children (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a> (75); <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a> (189)) and the control arm size was 335 (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a> (84), <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a> (251)). The rimantadine arm size was 27 and the control arm size was 29 children for these adverse effects (<a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>). </p> </section> <section id="CD002745-sec-0057"> <h5 class="title">Trials in the elderly</h5> <p>We selected three trials in this age group that reported on prophylaxis with rimantadine; we did not select any treatment trials. We studied the following outcomes. </p> <p> <ol id="CD002745-list-0005"> <li> <p>Prophylaxis of laboratory and clinical infection (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>). </p> </li> <li> <p>Adverse reactions (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>). </p> </li> <li> <p>Different doses of rimantadine as a prophylactic antiviral (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>). </p> </li> <li> <p>Comparison to other antivirals in the prophylaxis of influenza (<a href="./references#CD002745-bbs2-0005" title="GravensteinS , DrinkaP , OsterweilD , SchillingM , KrauseP , ElliotM , et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long‐term care population. Journal of the American Medical Directors Association2005;6:359‐66. ">Gravenstein 2005</a>; <a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a>). </p> </li> </ol> </p> <p>For prophylaxis of laboratory and clinical infection, the rimantadine (200 mg/day) arm size was 44 (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a> (26); <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a> (18)) and the placebo arm size was 31 participants (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a> (14); <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a> (17)). The trial authors stated they limited this analysis to vaccinated participants in nursing homes with confirmed influenza, as it provided an estimate of the additional protective efficacy of rimantadine. The sample studied by <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a> was made up of previously vaccinated participants, so all the participants were analysed (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>). </p> <p>In the adverse reaction studies focusing on stimulation/insomnia, confusion, fatigue, nausea, depression, loss of appetite and vomiting, the rimantadine (200 mg/day) arm size was 150 (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a> (132); <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a> (18)) and the placebo arm size was 83 participants (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a> (66); <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a> (17)). All randomly assigned participants were analysed. </p> <p>In the adverse reaction study focusing on headache, impaired concentration, rash or allergic reaction, seizures or clonic twitching, the rimantadine (200 mg/day) arm size was 132 and the placebo arm size was 66 participants (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>). </p> <p>In another adverse reaction study focusing on dizziness and anxiety, the rimantadine (200 mg/day) arm size was 18 and the placebo arm size was 17 participants (<a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>). </p> <p>In the unique study evaluating different doses of rimantadine as a prophylactic drug for clinical and confirmed influenza A, the rimantadine (100 mg/day) arm size was 28 and the rimantadine (200 mg/day) arm size was 26 participants (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>). </p> <p>Only one selected study focused on adverse effects related to different doses of rimantadine. The studied effects were confusion, depression, impaired concentration, insomnia or sleeplessness, loss of appetite, rash or allergic reaction, seizure or clonic twitching, dry mouth, fatigue or drowsiness, headache, body weakness and debility. The 100 mg/day arm size was 130 and the 200 mg/day arm size was 132 participants (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>). </p> <p>We selected two trials for the comparison of rimantadine to another antiviral and the participants were also the elderly (<a href="./references#CD002745-bbs2-0005" title="GravensteinS , DrinkaP , OsterweilD , SchillingM , KrauseP , ElliotM , et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long‐term care population. Journal of the American Medical Directors Association2005;6:359‐66. ">Gravenstein 2005</a>; <a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a>). The rimantadine arm size was 254 and the zanamivir arm size was 291 participants. No study used amantadine for this kind of comparison. </p> </section> </section> <section id="CD002745-sec-0058"> <h4 class="title">Excluded studies</h4> <p>We excluded 212 studies for the following reasons.</p> <p> <ol id="CD002745-list-0006"> <li> <p>They were carried out in different age groups.</p> </li> <li> <p>They were not controlled trials.</p> </li> <li> <p>They assessed other drugs.</p> </li> <li> <p>They were non‐human or laboratory studies.</p> </li> </ol> </p> <p>We excluded 20 new trials in this 2014 update (<a href="./references#CD002745-bbs2-0017" title="AntonA , PumarolaT . Influenza in immunocompromised patients: Considerations for therapy. Future Virology2011;6:855‐68. ">Anton 2011</a>; <a href="./references#CD002745-bbs2-0021" title="AtieeG , LasseterK , BaughmanS , McCulloughA , CollisP , HollisterA , et al. Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans. Journal of Clinical Pharmacology2012;52:1410‐9. ">Atiee 2012</a>; <a href="./references#CD002745-bbs2-0023" title="BacosiM , RussoF , D'InnocenzoS , SantolamazzaM , MiglioresiL , UrsittiA , et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatology Research2002;22:231‐9. ">Bacosi 2002</a>; <a href="./references#CD002745-bbs2-0041" title="Cayley JrWE . Are neuraminidase inhibitors effective for preventing and treating influenza in healthy adults and children?. American Family Physician2012;86:624‐6. ">Cayley 2012</a>; <a href="./references#CD002745-bbs2-0047" title="ChengVCC , ToKKW , TseH , HungIFN , YuenKY . Two years after pandemic influenza A/2009/H1N1: What have we learned?. Clinical Microbiology Reviews2012;25:223‐63. ">Cheng 2012</a>; <a href="./references#CD002745-bbs2-0058" title="DeVincenzoJP . The promise, pitfalls and progress of RNA‐interference‐based antiviral therapy for respiratory viruses. Antiviral Therapy2012;17:213‐25. ">De Vincenzo 2012</a>; <a href="./references#CD002745-bbs2-0065" title="EscuretV , CornuC , BoutitieF , EnoufV , MosnierA , Bouscambert‐DuchampM , et al. Oseltamivir‐zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A (H1N1) virus infections. Antiviral Research2012;96:130‐7. ">Escuret 2012</a>; <a href="./references#CD002745-bbs2-0076" title="GatwoodJ , MeltzerMI , MessonnierM , Ortega‐SanchezIR , BalkrishnanR , ProsserLA . Seasonal influenza vaccination of healthy working‐age adults: a review of economic evaluations. Drugs2012;72:35‐48. ">Gatwood 2012</a>; <a href="./references#CD002745-bbs2-0091" title="HaydenFG . Experimental human influenza: Observations from studies of influenza antivirals. Antiviral Therapy2012;17:133‐41. ">Hayden 2012</a>; <a href="./references#CD002745-bbs2-0096" title="HsuJ , SantessoN , MustafaR , BrozekJ , ChenYL , HopkinsJP , et al. Antivirals for treatment of influenza: a systematic review and meta‐analysis of observational studies. Annals of Internal Medicine2012;156:512‐24. ">Hsu 2012</a>; <a href="./references#CD002745-bbs2-0103" title="IsonMG . Clinical use of approved influenza antivirals: therapy and prophylaxis. Influenza &amp; Other Respiratory Viruses2013;7(Suppl 1):7‐13. ">Ison 2013</a>; <a href="./references#CD002745-bbs2-0107" title="JiangL , DengL , WuT . Chinese medicinal herbs for influenza. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD004559.pub4] ">Jiang 2013</a>; <a href="./references#CD002745-bbs2-0135" title="Lopez‐MedranoF , Carmen FarinasM , PayerasA , PachonJ . Antiviral treatment and vaccination for influenza A (H1N1) pdm09 virus: lessons learned from the pandemic. Enfermedades Infecciosas y Microbiologia Clinica2012;30:49‐53. ">Lopez‐Medrano 2012</a>; <a href="./references#CD002745-bbs2-0136" title="LouieJK , YangS , YenC , AcostaM , SchechterR , UyekiTM . Use of intravenous peramivir for treatment of severe influenza A (H1N1) pdm09. PloS One2012;7(6):e40261. ">Louie 2012</a>; <a href="./references#CD002745-bbs2-0150" title="MichielsB , vanPuyenbroeckK , VerhoevenV , VermeireE , CoenenS . The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PloS One2013;8(4):e60348. ">Michiels 2013</a>; <a href="./references#CD002745-bbs2-0179" title="SampaioC , BronzovaJ , HauserRA , LangAE , RascolO , van deWitteSV , et al. Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials. Movement Disorders2011;26:1464‐76. ">Sampaio 2011</a>; <a href="./references#CD002745-bbs2-0180" title="SantessoN , HsuJ , MustafaR , BrozekJ , ChenYL , HopkinsJP , et al. Antivirals for influenza: A summary of a systematic review and meta‐analysis of observational studies. Influenza and other Respiratory Viruses2013;7:76‐81. ">Santesso 2013</a>; <a href="./references#CD002745-bbs2-0188" title="ShahDP , GhantojiSS , MulanovichVE , Ariza‐HerediaEJ , ChemalyRF . Management of respiratory viral infections in hematopoietic cell transplant recipients. American Journal of Blood Research2012;2:203‐18. ">Shah 2012</a>; <a href="./references#CD002745-bbs2-0192" title="SingerB , RossAP , TobiasK . Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis. International Journal of Clinical Practice2011;65:887‐95. ">Singer 2011</a>; <a href="./references#CD002745-bbs2-0223" title="YuenC , ChanY , TambyahPA . Preflucel (registered trademark): a Vero‐cell culture‐derived trivalent influenza vaccine. Expert Review of Vaccines2012;11:759‐73. ">Yuen 2012</a>). </p> </section> </section> <section id="CD002745-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>The overall risk of bias is presented graphically in <a href="#CD002745-fig-0001">Figure 1</a> and summarised in <a href="#CD002745-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD002745-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002745-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD002745-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002745-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD002745-sec-0060"> <h4 class="title">Allocation</h4> <p>The trial authors of the 12 included studies stated that participants had been randomly allocated into treatment or control groups. In two of the studies we obtained the following information by contacting the trial authors (<a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>; <a href="./references#CD002745-bbs2-0011" title="PaylerDK , PurdhamPA . Influenza A prophylaxis with amantadine in a boarding school. Lancet1984;1(8375):502‐4. ">Payler 1984</a>). Hall reported that a computer system was used to randomise participants. The university pharmacy was chosen to allocate and store the study drugs (<a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>). In Payler's study, randomisation had been carried out by the statistical department of a pharmaceutical company, which kept the key to the randomisation and only when the study was analysed was the code broken (<a href="./references#CD002745-bbs2-0011" title="PaylerDK , PurdhamPA . Influenza A prophylaxis with amantadine in a boarding school. Lancet1984;1(8375):502‐4. ">Payler 1984</a>). There was no mention of any particular randomisation method in the other studies. </p> </section> <section id="CD002745-sec-0061"> <h4 class="title">Blinding</h4> <p>Ten studies were described as double‐blinded (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0002" title="CloverRD , WarnerJL , BeckerL , DavisA . Effect of rimantadine on the immune response to influenza A infections. Journal of Medical Virology1991;34(1):68‐73. [MEDLINE: 1885945] ">Clover 1991</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>; <a href="./references#CD002745-bbs2-0004" title="FinkleaJF , HennessyAV , DavenportFM . A field trial of amantadine prophylaxis in naturally‐occurring acute respiratory illness. American Journal of Epidemiology1967;85:403‐12. [5337715] ">Finklea 1967</a>; <a href="./references#CD002745-bbs2-0005" title="GravensteinS , DrinkaP , OsterweilD , SchillingM , KrauseP , ElliotM , et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long‐term care population. Journal of the American Medical Directors Association2005;6:359‐66. ">Gravenstein 2005</a>; <a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>; <a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>; <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a>; <a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>). However, only in one trial were blinded people listed (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>). Although there was no blinding stated in <a href="./references#CD002745-bbs2-0011" title="PaylerDK , PurdhamPA . Influenza A prophylaxis with amantadine in a boarding school. Lancet1984;1(8375):502‐4. ">Payler 1984</a>, we judged that the outcome was not likely to be influenced by a lack of blinding. <a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a> was described as an unblinded study; we also judged that the outcomes were unlikely to be influenced by a lack of blinding. </p> </section> <section id="CD002745-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>There were no missing participants in either <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a>, <a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a> or <a href="./references#CD002745-bbs2-0011" title="PaylerDK , PurdhamPA . Influenza A prophylaxis with amantadine in a boarding school. Lancet1984;1(8375):502‐4. ">Payler 1984</a>. The review authors considered that the reasons for missing outcome data were unlikely to be related to true outcome in the following studies: <a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0002" title="CloverRD , WarnerJL , BeckerL , DavisA . Effect of rimantadine on the immune response to influenza A infections. Journal of Medical Virology1991;34(1):68‐73. [MEDLINE: 1885945] ">Clover 1991</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>; <a href="./references#CD002745-bbs2-0004" title="FinkleaJF , HennessyAV , DavenportFM . A field trial of amantadine prophylaxis in naturally‐occurring acute respiratory illness. American Journal of Epidemiology1967;85:403‐12. [5337715] ">Finklea 1967</a>; <a href="./references#CD002745-bbs2-0005" title="GravensteinS , DrinkaP , OsterweilD , SchillingM , KrauseP , ElliotM , et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long‐term care population. Journal of the American Medical Directors Association2005;6:359‐66. ">Gravenstein 2005</a>. In the <a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a> trial, we considered that the proportion of missing outcomes compared with observed event risk was not enough to have a clinically relevant impact on the intervention effect estimate. On the other hand, we considered the reasons for missing outcome data likely to be related to the true outcome data in two studies (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>). In <a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a>, there was insufficient reporting of exclusion. </p> </section> <section id="CD002745-sec-0063"> <h4 class="title">Selective reporting</h4> <p>The review authors did not identify any possible sources of reporting biases.</p> </section> <section id="CD002745-sec-0064"> <h4 class="title">Other potential sources of bias</h4> <p>The review authors did not identify any other possible sources of bias.</p> </section> </section> <section id="CD002745-sec-0065"> <h3 class="title" id="CD002745-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD002745-tbl-0001"><b>Summary of findings for the main comparison</b> </a>; <a href="./full#CD002745-tbl-0002"><b>Summary of findings 2</b> </a>; <a href="./full#CD002745-tbl-0003"><b>Summary of findings 3</b> </a>; <a href="./full#CD002745-tbl-0004"><b>Summary of findings 4</b> </a> </p> <section id="CD002745-sec-0066"> <h4 class="title">Primary outcomes in children</h4> <section id="CD002745-sec-0067"> <h5 class="title">Amantadine and rimantadine compared to control (placebo and acetaminophen) in the treatment of influenza A in children </h5> <p>In the protocol, we originally planned to study the drug effect on reduction of fever and cough as they are considered the best predictors of influenza diagnosis. After collecting data, we verified that specific timelines for reduction of signs and symptoms were not reported in the included trials. We searched for another way to present an estimation of the response to amantadine and rimantadine in patients with influenza. For this unplanned analysis, we considered the available data and arbitrarily chose a day of antiviral use to evaluate the response to the treatment. This choice was based on the <a href="./references#CD002745-bbs2-0238" title="EccleR . Understanding the symptoms of the common cold and influenza. Lancet Infectious Diseases2005;5:718‐25. ">Eccle 2005</a> study in which clinical manifestations were classified into early and later symptoms. Typically fever may last four to eight days, so we chose day three of treatment as the cut‐off point to which it could be considered that the response to the drug would be useful. Cough is considered a later manifestation that develops slowly and can still be present a week later (<a href="./references#CD002745-bbs2-0238" title="EccleR . Understanding the symptoms of the common cold and influenza. Lancet Infectious Diseases2005;5:718‐25. ">Eccle 2005</a>). In the same way, we chose day seven of treatment as the cut‐off point by when the response to the drug could be considered useful. </p> <p>We also decided to include other treatment outcomes as they were available in Hall's electronic correspondence to us. In the same way, we arbitrarily chose a day of antiviral use to evaluate the response to the treatment to make this unplanned analysis: 'malaise on day six', as it begins early but could still be present for one or two weeks (<a href="./references#CD002745-bbs2-0238" title="EccleR . Understanding the symptoms of the common cold and influenza. Lancet Infectious Diseases2005;5:718‐25. ">Eccle 2005</a>; <a href="./references#CD002745-bbs2-0260" title="SmithNM , BreseeJJ , ShayDK , UyekiTM , CoxNJ , StrikasRA . Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practice (ACIP). Morbidity and Mortality Weekly Report: Recommendations and Reports/Centers for Disease Control2006;55(RR10):1‐42. [ISSN 1545‐8601 (Electronic)] ">Smith 2006</a>), and 'eye manifestations on day five', as it can occur early on in the course of the illness (<a href="./references#CD002745-bbs2-0262" title="TreanorJJ . Influenza viruses. In: Mandell , Bennett , &amp;Dolin editor(s). Principles and Practice of Infectious Diseases. 6th Edition. Vol. 2, W.B. Saunders, an imprint of Elsevier, 2005:2060‐85. ">Treanor 2005</a>; <a href="./references#CD002745-bbs2-0270" title="WrightP . Influenza viruses. In: BehrmanRE , KliegmanRM , HallBJ editor(s). Nelson Textbook of Pediatrics of Pediatrics. 17th Edition. Saunders (an imprint of Elsevier), 2004:1072‐5. ">Wright 2004</a>) </p> <p>Amantadine was compared to placebo: 104 participants (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>; <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a>), and rimantadine to acetaminophen: 69 participants (<a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>). </p> <p>There was a protective effect of amantadine and rimantadine in the occurrence of fever on day three of antiviral treatment, when trials using both antivirals were combined: 173 participants, risk ratio (RR) 0.39; 95% confidence interval (CI) 0.20 to 0.79 (<a href="./references#CD002745-fig-0003" title="">Analysis 1.1</a>) (<a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>; <a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>; <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a>). </p> <p>The baseline risk of fever on day three of treatment was 0.28, calculated on the basis of the control group risk (CGR). The number of children needed to treat to benefit (NNTB) to prevent one case of fever on day three of treatment was six (95% CI 4 to 17) (<a href="./references#CD002745-fig-0003" title="">Analysis 1.1</a>). </p> <p>We also verified a protective effect of rimantadine for this outcome: RR 0.36; 95% CI 0.14 to 0.91 (<a href="./references#CD002745-fig-0003" title="">Analysis 1.1</a>.2). The baseline risk of fever on day three of treatment was 0.38, calculated on the basis of the CGR. The NNTB was five (95% CI 3 to 25) (<a href="./references#CD002745-fig-0003" title="">Analysis 1.1</a>). Just one trial with 69 participants reported this outcome (<a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>). </p> <p>We observed no protective effect of amantadine in the occurrence of fever on day three of treatment: 104 participants, RR 0.37; 95% CI 0.08 to 1.75 (<a href="./references#CD002745-fig-0003" title="">Analysis 1.1</a>.1) (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>; <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a>). </p> <p>We saw no protective effect of rimantadine regarding the occurrence of any of the following outcomes assessed: malaise on day six (RR 1.04; 95% CI 0.63 to 1.70) (<a href="./references#CD002745-fig-0004" title="">Analysis 1.2</a>), cough on day seven (RR 0.83; 95% CI 0.63 to 1.10) (<a href="./references#CD002745-fig-0005" title="">Analysis 1.3</a>), conjunctivitis on day five (RR 0.17; 95% CI 0.01 to 3.49) (<a href="./references#CD002745-fig-0006" title="">Analysis 1.4</a>), and cases of pain on movement and visual distortion on day five (RR 0.58; 95% CI 0.10 to 3.24) (<a href="./references#CD002745-fig-0007" title="">Analysis 1.5</a>). Just one study with 69 participants reported these outcomes (<a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>). </p> <p>No selected studies reported the use of amantadine for these latter outcomes.</p> </section> <section id="CD002745-sec-0068"> <h5 class="title">Amantadine and rimantadine compared to control in the treatment of influenza A in the elderly </h5> <p>There was no study selected for this comparison.</p> </section> <section id="CD002745-sec-0069"> <h5 class="title">Amantadine and rimantadine compared to control (placebo and to specific treatment) in the prophylaxis of influenza A in children </h5> <p>Amantadine was compared to placebo and specific treatment (<a href="./references#CD002745-bbs2-0004" title="FinkleaJF , HennessyAV , DavenportFM . A field trial of amantadine prophylaxis in naturally‐occurring acute respiratory illness. American Journal of Epidemiology1967;85:403‐12. [5337715] ">Finklea 1967</a>; <a href="./references#CD002745-bbs2-0011" title="PaylerDK , PurdhamPA . Influenza A prophylaxis with amantadine in a boarding school. Lancet1984;1(8375):502‐4. ">Payler 1984</a>) and rimantadine to placebo (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0002" title="CloverRD , WarnerJL , BeckerL , DavisA . Effect of rimantadine on the immune response to influenza A infections. Journal of Medical Virology1991;34(1):68‐73. [MEDLINE: 1885945] ">Clover 1991</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>). </p> <p>The amantadine (<a href="./references#CD002745-bbs2-0004" title="FinkleaJF , HennessyAV , DavenportFM . A field trial of amantadine prophylaxis in naturally‐occurring acute respiratory illness. American Journal of Epidemiology1967;85:403‐12. [5337715] ">Finklea 1967</a>; <a href="./references#CD002745-bbs2-0011" title="PaylerDK , PurdhamPA . Influenza A prophylaxis with amantadine in a boarding school. Lancet1984;1(8375):502‐4. ">Payler 1984</a>) and rimantadine trials (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0002" title="CloverRD , WarnerJL , BeckerL , DavisA . Effect of rimantadine on the immune response to influenza A infections. Journal of Medical Virology1991;34(1):68‐73. [MEDLINE: 1885945] ">Clover 1991</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>) were heterogeneous (Chi<sup>2</sup> test 9.27, P value = 0.05, I<sup>2</sup> statistic 56.8%) and could not be combined. </p> <p>A protective effect of amantadine was observed with 773 participants, RR 0.11; 95% CI 0.04 to 0.30 (<a href="./references#CD002745-fig-0008" title="">Analysis 2.1</a>.1). The baseline risk of influenza was 0.10, calculated on the basis of the CGR. The NNTB was 12 (95% CI 9 to 17) for a period ranging from 14 (<a href="./references#CD002745-bbs2-0011" title="PaylerDK , PurdhamPA . Influenza A prophylaxis with amantadine in a boarding school. Lancet1984;1(8375):502‐4. ">Payler 1984</a>) to 18 weeks (<a href="./references#CD002745-bbs2-0004" title="FinkleaJF , HennessyAV , DavenportFM . A field trial of amantadine prophylaxis in naturally‐occurring acute respiratory illness. American Journal of Epidemiology1967;85:403‐12. [5337715] ">Finklea 1967</a>). </p> <p>On the other hand, no protective effect of rimantadine was seen in the prophylaxis of cases of influenza: 178 participants (RR 0.49; 95% CI 0.21 to 1.15) (<a href="./references#CD002745-fig-0008" title="">Analysis 2.1</a>.2) (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0002" title="CloverRD , WarnerJL , BeckerL , DavisA . Effect of rimantadine on the immune response to influenza A infections. Journal of Medical Virology1991;34(1):68‐73. [MEDLINE: 1885945] ">Clover 1991</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>). </p> </section> <section id="CD002745-sec-0070"> <h5 class="title">Use of different doses of amantadine and rimantadine for prophylaxis and treatment of influenza in children </h5> <p>There was no selected study conducted in children for this comparison.</p> </section> <section id="CD002745-sec-0071"> <h5 class="title">Amantadine and rimantadine compared to other antivirals in children</h5> <p>There was no selected study conducted in children for this comparison</p> </section> <section id="CD002745-sec-0072"> <h5 class="title">Amantadine and rimantadine compared to control (placebo and zanamivir) in the prophylaxis of influenza A in the elderly </h5> <p>Rimantadine was compared to placebo (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>) and to zanamivir (<a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a>). No protective effect of rimantadine was seen regarding the prophylaxis of influenza in the elderly: 191 participants, RR 0.74; 95% CI 0.13 to 4.07 (<a href="./references#CD002745-fig-0009" title="">Analysis 3.1</a>). </p> <p>Although care must be taken in the interpretation of the Chi<sup>2</sup> test due to its low power in detecting heterogeneity in meta‐analyses, we should emphasise the high P value observed in this comparison, considered alongside the I<sup>2</sup> statistic value under 50%: Chi<sup>2</sup> test 3.28; P value = 0.19, I<sup>2</sup> statistic 39%. We decided to explore the reasons for these findings as if the studies were heterogeneous, even though it would result in smaller samples impairing the ability to reach any definitive conclusion (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>; <a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a>). </p> <p>Monto and Patriarca analysed previously vaccinated participants in blinded trials and used a placebo as control (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>). Schilling did not state if the participants were vaccinated, although it was stated that the majority of the studied population had been previously immunised (<a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a>). This was an unblinded trial in which another antiviral (zanamivir) was used as a control drug. </p> <p>When we excluded this study (<a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a>), the remaining trials, <a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a> and <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a> were shown to be homogeneous but no protective effect of rimantadine prophylaxis in the occurrence of cases of influenza persisted (103 participants, RR 0.45; 95% CI 0.14 to 1.41) (<a href="./references#CD002745-fig-0010" title="">Analysis 3.2</a>). </p> <p><a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a> used two different doses of rimantadine in his trial (100 mg/day and 200 mg/day) and <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a> used the conventional dose of 200 mg/day. <a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a> used a single dose of 100 mg/day. We also combined Monto's 200 mg/day subgroup with Patriarca's study in which the same dose was administered, but again no protective effect of rimantadine was observed in the prophylaxis of influenza: eight participants, RR 0.44; 95% CI 0.12 to 1.63) (<a href="./references#CD002745-fig-0011" title="">Analysis 3.3</a>) (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>; <a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a>). </p> <p>Schilling's sample and Monto's 100 mg/day subgroup were heterogeneous and could not be combined (Chi<sup>2</sup> test 2.55, P value = 0.11, I<sup>2</sup> statistic 60.8%) (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a>). </p> <p>There was no amantadine study selected for comparison.</p> </section> <section id="CD002745-sec-0073"> <h5 class="title">Use of different doses of amantadine and rimantadine for prophylaxis and treatment of influenza A in the elderly </h5> <p>A reduced rimantadine dose of 100 mg/day was comparable to the full dose of 200 mg daily for prophylaxis of influenza in the elderly, although a wide CI was verified (54 participants, RR 0.93; 95% CI 0.21 to 4.20) (<a href="./references#CD002745-fig-0013" title="">Analysis 4.1</a>). It should be emphasised that there were few data available for these comparisons (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>). </p> <p>There was no selected study using different doses of rimantadine in the elderly, nor any selected trial comparing different doses of amantadine for prophylaxis and treatment of influenza in the elderly. </p> </section> <section id="CD002745-sec-0074"> <h5 class="title">Amantadine and rimantadine compared to other antivirals in the elderly</h5> <p>In Gravenstein's but not in Schilling's study an identical placebo was used (<a href="./references#CD002745-bbs2-0005" title="GravensteinS , DrinkaP , OsterweilD , SchillingM , KrauseP , ElliotM , et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long‐term care population. Journal of the American Medical Directors Association2005;6:359‐66. ">Gravenstein 2005</a>; <a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a>). When rimantadine was compared to zanamivir it was shown that zanamivir prevented influenza A more effectively than rimantadine in the elderly (<a href="./references#CD002745-fig-0014" title="">Analysis 5.1</a>). </p> <p>There was no amantadine trial selected for this comparison in the elderly.</p> </section> <section id="CD002745-sec-0075"> <h5 class="title">Adverse effects of amantadine and rimantadine compared to control (placebo and acetaminophen) in children </h5> <p>Amantadine was compared to placebo (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>; <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a>). Rimantadine was compared to placebo (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>) and to acetaminophen (<a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>). </p> <p>Amantadine was not related to a higher risk of the following adverse effects in two trials with 599 participants: diarrhoea (RR 0.79; 95% CI 0.42 to 1.47) (<a href="./references#CD002745-fig-0015" title="">Analysis 6.1</a>), exanthema (RR 0.69; 95% CI 0.21 to 2.34) (<a href="./references#CD002745-fig-0016" title="">Analysis 6.2</a>), muscular limb pain (RR 0.85; 95% CI 0.46 to 1.59) (<a href="./references#CD002745-fig-0017" title="">Analysis 6.3</a>), headache (RR 0.73; 95% CI 0.52 to 1.03) (<a href="./references#CD002745-fig-0018" title="">Analysis 6.4</a>) and stimulation and insomnia (RR 0.46; 95% CI 0.12 to 1.74) (<a href="./references#CD002745-fig-0019" title="">Analysis 6.5</a>) (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>; <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a>). </p> <p>In the same way, amantadine was not related to the outcomes dizziness and dyspnoea. For dizziness there were 655 participants in two studies (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>; <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a>). The RR was 6.63 (95% CI 0.32 to 137.33) (<a href="./references#CD002745-fig-0020" title="">Analysis 6.6</a>.1) and for dyspnoea there were 159 participants in just one trial (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>). The RR was 0.37 (95% CI 0.02 to 9.02) (<a href="./references#CD002745-fig-0021" title="">Analysis 6.7</a>). </p> <p>The studies were heterogeneous for the outcomes malaise (Chi<sup>2</sup> test 3.75, P value = 0.05, I<sup>2</sup> statistic 73.3%) and nausea/vomiting (Chi<sup>2</sup> test 4.26, P value = 0.04, I<sup>2</sup> statistic 76.5%), although it seems that the author had used the same protocol. Nevertheless, the heterogeneity for the outcome nausea/vomiting does not seem to be relevant, as amantadine could be related either to an increase or to a reduction in the occurrence of this adverse effect (<a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>; <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a>). </p> <p>No cases of arrhythmia were reported in those two trials.</p> <p>Rimantadine was not related to a higher risk of any of the following adverse effects assessed: central nervous system (CNS) symptoms: one study, 76 participants (RR 0.23; 95% CI 0.01 to 4.70) (<a href="./references#CD002745-fig-0022" title="">Analysis 6.8</a>); change in behaviour: one study, 76 participants (RR 0.23; 95% CI 0.01 to 4.70) (<a href="./references#CD002745-fig-0023" title="">Analysis 6.9</a>); diarrhoea: one study, 56 participants (RR 0.36; 95% CI 0.02 to 8.41) (<a href="./references#CD002745-fig-0015" title="">Analysis 6.1</a>.2); dizziness: one study, 56 participants (RR 3.21; 95% CI 0.14 to 75.68) (<a href="./references#CD002745-fig-0020" title="">Analysis 6.6</a>.2); gastro‐intestinal (GI) manifestations: one study, 76 participants (RR 1.17; 95% CI 0.08 to 18.05) (<a href="./references#CD002745-fig-0024" title="">Analysis 6.10</a>); hyperactivity: one study, 56 participants (RR 0.36; 95% CI 0.02 to 8.41) (<a href="./references#CD002745-fig-0025" title="">Analysis 6.11</a>); tinnitus: one study, 56 participants (RR 3.21; 95% CI 0.14 to 75.68) (<a href="./references#CD002745-fig-0026" title="">Analysis 6.12</a>); cerebellar ataxia: one study, 69 participants (RR 2.61; 95% CI 0.11 to 61.80) (<a href="./references#CD002745-fig-0027" title="">Analysis 6.13</a>) (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>; <a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>). </p> <p>As it was stated, each one of the adverse effects described above was studied in just one included trial, except for nausea and vomiting (<a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>; <a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>). In the same way, rimantadine was not related to a higher risk of nausea and vomiting: two studies, 125 participants (RR 0.96; 95% CI 0.10 to 9.01) (<a href="./references#CD002745-fig-0029" title="">Analysis 6.15</a>.2). </p> </section> <section id="CD002745-sec-0076"> <h5 class="title">Adverse effects related to different doses of amantadine and rimantadine in children</h5> <p>There were no selected studies conducted in children for this comparison.</p> </section> <section id="CD002745-sec-0077"> <h5 class="title">Adverse effects of amantadine and rimantadine compared to control (placebo) in the elderly </h5> <p>There were two selected studies for these outcomes, both using rimantadine and placebo (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>). </p> <p>No effect of rimantadine was seen regarding any of the adverse outcomes assessed in the combined studies: stimulation and insomnia (233 participants, RR 1.61; 95% CI 0.43 to 6.02) (<a href="./references#CD002745-fig-0031" title="">Analysis 7.1</a>), confusion (233 participants, RR 0.79; 95% CI 95% 0.40 to 1.56) (<a href="./references#CD002745-fig-0032" title="">Analysis 7.2</a>), fatigue (233 participants, RR 0.81; 95% CI 0.41 to 1.60) (<a href="./references#CD002745-fig-0033" title="">Analysis 7.3</a>) and vomiting (233 participants, RR 0.99; 95% CI 0.38 to 2.60) (<a href="./references#CD002745-fig-0034" title="">Analysis 7.4</a>) (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>). </p> <p>In the same way, rimantadine was not related to the outcomes studied by Monto: headache (198 participants, RR 0.83; 95% CI 0.21 to 3.38) (<a href="./references#CD002745-fig-0035" title="">Analysis 7.5</a>); impaired concentration (198 participants, RR 0.50; 95% CI 0.10 to 2.41) (<a href="./references#CD002745-fig-0036" title="">Analysis 7.6</a>); rash or allergic reaction (198 participants, RR 3.53; 95% CI 0.18 to 67.28) (<a href="./references#CD002745-fig-0037" title="">Analysis 7.7</a>); seizures or clonic twitching (198 participants, RR 2.00; 95% CI 0.23 to 17.54) (<a href="./references#CD002745-fig-0038" title="">Analysis 7.8</a>) and dry mouth (198 participants, RR 0.70; 95% CI 0.23 to 2.12) (<a href="./references#CD002745-fig-0039" title="">Analysis 7.9</a>), as well as in those studied by Patriarca: dizziness (35 participants, RR 0.94; 95% CI 0.15 to 5.97) (<a href="./references#CD002745-fig-0040" title="">Analysis 7.10</a>) and anxiety (35 participants, RR 2.83; 95% CI 0.92 to 8.74) (<a href="./references#CD002745-fig-0041" title="">Analysis 7.11</a>) (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>). </p> <p>The articles were heterogeneous just for the occurrence of nausea (test for heterogeneity: Chi<sup>2</sup> test 2.02; P value = 0.16; I<sup>2</sup> statistic 50.5%). Nevertheless, this heterogeneity does not seem to be relevant as rimantadine could be related either to an increase or to a reduction in the occurrence of nausea in each one of the studies (<a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>: 35 participants, RR 5.67; 95% CI 0.76 to 42.32 and <a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>: 198 participants, RR 1.17; 95% CI 0.47 to 2.90) (<a href="./references#CD002745-fig-0042" title="">Analysis 7.12</a>). </p> <p>It is important to stress the small samples studied in both trials. There was no amantadine trial selected for comparison. </p> </section> <section id="CD002745-sec-0078"> <h5 class="title">Adverse effects related to different doses of amantadine and rimantadine in the elderly</h5> <p>There was no protective effect of a reduced dose of rimantadine in the occurrence of the following adverse reactions in the elderly: one study with 262 participants: confusion (RR 0.82; 95% CI 0.41 to 1.65) (<a href="./references#CD002745-fig-0045" title="">Analysis 8.1</a>), depression (RR 0.44; 95% CI 0.12 to 1.65) (<a href="./references#CD002745-fig-0046" title="">Analysis 8.2</a>), impaired concentration (RR 0.68; 95% CI 0.11 to 3.98) (<a href="./references#CD002745-fig-0047" title="">Analysis 8.3</a>), insomnia or sleeplessness (RR 1.02; 95% CI 0.26 to 3.97) (<a href="./references#CD002745-fig-0048" title="">Analysis 8.4</a>), loss of appetite (RR 0.62; 95% CI 0.27 to 1.46) (<a href="./references#CD002745-fig-0049" title="">Analysis 8.5</a>), rash or allergic reaction (RR 0.34; 95% CI 0.04 to 3.21) (<a href="./references#CD002745-fig-0050" title="">Analysis 8.6</a>), seizures or clonic twitching (RR 0.11; 95% CI 0.01 to 2.07) (<a href="./references#CD002745-fig-0051" title="">Analysis 8.7</a>), dry mouth (RR 1.16; 95% CI 0.43 to 3.11) (<a href="./references#CD002745-fig-0052" title="">Analysis 8.8</a>), fatigue or drowsiness (RR 1.14; 95% CI 0.45 to 2.87) (<a href="./references#CD002745-fig-0053" title="">Analysis 8.9</a>), headache (RR 1.02; 95% CI 0.30 to 3.42) (<a href="./references#CD002745-fig-0054" title="">Analysis 8.10</a>) and body weakness or debility (RR 0.91; 95% CI 0.38 to 2.18) (<a href="./references#CD002745-fig-0055" title="">Analysis 8.11</a>) (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>). </p> <p>There was no amantadine trial selected for this comparison in the elderly.</p> </section> </section> <section id="CD002745-sec-0079"> <h4 class="title">Additional outcome (children plus the elderly)</h4> <section id="CD002745-sec-0080"> <h5 class="title">Rimantadine compared to control (placebo) in the prophylaxis of influenza A in children and the elderly </h5> <p>Originally in the protocol we planned only to make the above 12 comparisons. However, whilst analysing the data we considered doing an additional comparison and put the two age groups together. As the small samples studied in rimantadine trials for prophylaxis might have influenced the observed results, we tried to overcome this limitation by combining the trials with rimantadine in children and in the elderly. Rimantadine had no proven effect in preventing influenza in either age group but could be effective when we combined the results from both groups. However, it must be stressed that extraneous characteristics between those groups, other than age or previous immunisations, may have occurred, impairing generalisation of these results. There were five studies selected for this comparison with 156 patients in the treatment group and 125 in the placebo control group (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0002" title="CloverRD , WarnerJL , BeckerL , DavisA . Effect of rimantadine on the immune response to influenza A infections. Journal of Medical Virology1991;34(1):68‐73. [MEDLINE: 1885945] ">Clover 1991</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>; <a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>). The combination of the trials showed a protective effect of rimantadine in preventing influenza A (281 participants, RR 0.49; 95% CI 0.27 to 0.92) (<a href="./references#CD002745-fig-0056" title="">Analysis 9.1</a>). </p> <p>The baseline risk of influenza A was 0.22, calculated on the basis of the CGR. The NNTB was 9.09 (95% CI 6.25 to 50). We should emphasise that the follow‐up period ranged from 3 to 11 weeks. </p> <p>The following secondary outcomes appeared in the protocol but in the end we did not consider them in the analysis, as they were not reported in the included trials: patients' well‐being, admission to hospital, general practitioner (GP) visits and other drugs used. We could not analyse deaths. Although cited by <a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>, they were included among other causes of withdrawal. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002745-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002745-sec-0081"></div> <section id="CD002745-sec-0082"> <h3 class="title" id="CD002745-sec-0082">Summary of main results</h3> <p>We used a comprehensive search strategy and made every effort to identify relevant studies. In the majority of our comparisons, drawing definitive conclusions was impaired by the small number of studies and participants. The studies demonstrated a decreased incidence of influenza A in children using amantadine during a period ranging from 14 to 18 weeks. The number needed to treat to benefit (NNTB) indicates that for every nine to 17 children receiving amantadine, one case of influenza A can be prevented. </p> <p>Rimantadine had no proven effect in preventing influenza in either age group but could be effective when we combined the results of both groups. Nevertheless, any inferences from combining these groups must be treated with considerable caution, as they are different clinical groups combined with a small number of studies. Extraneous characteristics between those groups, other than age or previous immunisations, may also have occurred impairing generalisation of these results. Multiple comparisons should also be taken into account in the interpretation of these results. </p> <p>When amantadine and rimantadine were combined, they appeared to prevent the occurrence of fever on day three in children. However, when analysed separately, this effect was confirmed only for rimantadine. It must be emphasised that there was just one rimantadine trial selected for this outcome (<a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>), in which the baseline risk for the occurrence of fever on day three was 38%. For every five children (ranging from three to 25) treated with rimantadine in this unique small sample, it would be possible to prevent one case of fever on day three of treatment. </p> </section> <section id="CD002745-sec-0083"> <h3 class="title" id="CD002745-sec-0083">Overall completeness and applicability of evidence</h3> <p>It could be suggested that amantadine is well tolerated by children, as its use was not related to an increase in the occurrence of the analysed adverse effects. Nevertheless, it may be difficult to distinguish between an adverse effect of the drug and a clinical manifestation of influenza itself. The outcomes muscular pain, headache, malaise, diarrhoea and nausea/vomiting may be adverse effects of amantadine as well as clinical manifestations of influenza in children (<a href="./references#CD002745-bbs2-0253" title="Ministério da Saúde 2006 (Brazilian Ministry of Health 2006). Human influenza and avian influenza [Influenza humana e influenza aviária]. Série F. Comunicação e Educação em Saúde2006. ">MS 2006</a>). In the same way, the outcome dyspnoea (as in <a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>) may also occur due to other respiratory diseases, such as asthma, since an asthmatic episode may be triggered by respiratory viruses. So we must emphasise that adverse effects of the drug and clinical manifestations of influenza may had been confounded, since the selected trials were carried out in ill children. </p> <p>Rimantadine, administered exclusively on a prophylactic basis, was not related to an increase in the occurrence of the analysed adverse effects. In contrast to amantadine studies, just nausea/vomiting could be confounded with influenza manifestations. The other adverse effects could not be confounded, as two of the three selected studies were about prophylaxis and were conducted in children without influenza (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>). The third study was the only one carried out in children with influenza (<a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>). Cerebellar ataxia and nausea/vomiting were the studied adverse effects in this trial. Cerebellar ataxia could not be confounded as it had not been described as an influenza manifestation. Cases of nausea/vomiting, which were also cited by Crawford, could have been confounded with influenza manifestations in Hall's article. The side effects nausea/vomiting were described in two studies (<a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>; <a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>), while all the other adverse effects were mentioned in just one: diarrhoea, dizziness, hyperreactivity, tinnitus (<a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>), gastrointestinal (GI) symptoms, central nervous system (CNS) symptoms, changes in behaviour (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>), and cerebellar ataxia (<a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>). Rimantadine also was considered to be well tolerated by the elderly, since it was not related to an increase in the incidence of adverse effects in this age group. However, the studied samples were even smaller in the elderly than in the children's age group and this fact may have influenced our results (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>). </p> <p>When analysing the adverse reactions to the antivirals, we could not even try to overcome the limitation of the small number of articles and the small samples studied by combining the results of both age groups, as the trial authors had described different outcomes (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>; <a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>; <a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>; <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a>; <a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>). </p> <p>Comparison of different doses of antiviral drugs was available only for rimantadine and was tested in only one study related to the elderly group. There was no selected trial regarding the treatment either in children or in participants using amantadine in both age groups. Both doses were shown to be comparable in the prophylaxis of influenza as well as in the occurrence of adverse effects, with no proven efficacy (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>). </p> <p>Data for comparison to other antivirals were available just for rimantadine and zanamivir for prophylaxis of influenza A in the elderly group. This fact allowed a comparison of drugs of the two different classes of antivirals: M2 ion channel inhibitors and neuraminidase inhibitors. Zanamivir more effectively prevented influenza A in the elderly group (<a href="./references#CD002745-bbs2-0005" title="GravensteinS , DrinkaP , OsterweilD , SchillingM , KrauseP , ElliotM , et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long‐term care population. Journal of the American Medical Directors Association2005;6:359‐66. ">Gravenstein 2005</a>; <a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a>). </p> <p>These antivirals proved to be effective prophylactics against influenza in the 1968 Hong Kong pandemic and in the 1977 pandemic‐like event 'Russian influenza'. Although the same resistance marker (Ser31Asn) was present in two isolates of influenza A (H5N1) obtained from patients in China in 2003 and in one lineage of avian and human H5N1 viruses in Thailand, Vietnam and Cambodia, most tested isolates from a second lineage that had been circulating in Indonesia, China, Mongolia, Russia and Turkey appear to be sensitive to amantadine (<a href="./references#CD002745-bbs2-0242" title="HaydenFG , KlimovA , TashiroM , HayA , MontoA , McKimm‐BreschkinJ , et al. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antiviral Therapy2005;10(8):873‐7. ">Hayden 2005</a>; <a href="./references#CD002745-bbs2-0250" title="LiQ , ZhouL , ZhouM , ChenZ , LiF , WuH , et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. New England Journal of Medicine2014;370:520‐32. ">Li 2014</a>). Furthermore, the next pandemic virus may be one that, like H2N2, is susceptible to this class of drug. If the circulating strain were known to be susceptible to M2 inhibitors, these drugs would offer a less costly alternative to other antivirals (neuraminidase inhibitors) for prophylaxis against influenza. </p> </section> <section id="CD002745-sec-0084"> <h3 class="title" id="CD002745-sec-0084">Quality of the evidence</h3> <p>We selected a total of 12 randomised controlled trials (RCTs) (2494 participants: 1586 children and adolescents and 908 elderly participants). </p> <p>The main factors that affect the strength of evidence are the sparsity of data and the unclear risk of selection bias (<a href="./references#CD002745-bbs2-0001" title="CloverRD , CrawfordSA , AbellTD , RamseyCNJr , GlezenWP , CouchRB . Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children1986;140(7):706‐9. [CN‐00043175] ">Clover 1986</a>; <a href="./references#CD002745-bbs2-0002" title="CloverRD , WarnerJL , BeckerL , DavisA . Effect of rimantadine on the immune response to influenza A infections. Journal of Medical Virology1991;34(1):68‐73. [MEDLINE: 1885945] ">Clover 1991</a>; <a href="./references#CD002745-bbs2-0003" title="CrawfordSA , CloverRD , AbellTD , RamseyCN , GlezenWP , CouchRB . Rimantadine prophylaxis in children: a follow up study. Pediatric Infectious Disease Journal1988;7(6):379‐83. [3292997] ">Crawford 1988</a>; <a href="./references#CD002745-bbs2-0004" title="FinkleaJF , HennessyAV , DavenportFM . A field trial of amantadine prophylaxis in naturally‐occurring acute respiratory illness. American Journal of Epidemiology1967;85:403‐12. [5337715] ">Finklea 1967</a>; <a href="./references#CD002745-bbs2-0005" title="GravensteinS , DrinkaP , OsterweilD , SchillingM , KrauseP , ElliotM , et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long‐term care population. Journal of the American Medical Directors Association2005;6:359‐66. ">Gravenstein 2005</a>; <a href="./references#CD002745-bbs2-0007" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in influenza A2‐double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1968;15(1):17‐26. [CN‐00004214] ">Kitamoto 1968</a>; <a href="./references#CD002745-bbs2-0008" title="KitamotoO . Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza ‐ double‐blind studies. Japanese Journal of Tuberculosis and Chest Diseases1971;17(1):1‐7. [CN‐0000725] ">Kitamoto 1971</a>; <a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>; <a href="./references#CD002745-bbs2-0012" title="SchillingM , PolvinelliL , KrauseP , GravensteinM , AmbrozaitisA , JonesHH , et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine1998;16:1771‐4. [9778755] ">Schilling 1998</a>). We classified two of these studies, both in the elderly, as high risk of bias because of incomplete outcome data (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>; <a href="./references#CD002745-bbs2-0010" title="PatriarcaPA , KaterNA , KendalAP , BregmanDJ , SmithJD , SikesRK . Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy1984;26(1):101‐3. [CN‐00035517] ">Patriarca 1984</a>) and a high probability of detection bias (<a href="./references#CD002745-bbs2-0009" title="MontoAS , OhmitSE , HornbuckleK , PearceCL . Safety and efficacy of long‐term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy1995;39:2224‐8. [CN‐00121619] ">Monto 1995</a>). We considered two trials, both in children and adolescents, to have a low risk of bias (<a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>; <a href="./references#CD002745-bbs2-0011" title="PaylerDK , PurdhamPA . Influenza A prophylaxis with amantadine in a boarding school. Lancet1984;1(8375):502‐4. ">Payler 1984</a>). </p> </section> <section id="CD002745-sec-0085"> <h3 class="title" id="CD002745-sec-0085">Potential biases in the review process</h3> <p>The use of unpublished data, obtained in electronic correspondence with two of the 12 contact trial authors (<a href="./references#CD002745-bbs2-0006" title="HallCB , DolinR , GalaCL , MarkovitzDM , ZhangYQ , MadorePH , et al. Children with influenza A infection: treatment with rimantadine. Pediatrics1987;80:275‐82. [CN‐00049308] ">Hall 1987</a>; <a href="./references#CD002745-bbs2-0011" title="PaylerDK , PurdhamPA . Influenza A prophylaxis with amantadine in a boarding school. Lancet1984;1(8375):502‐4. ">Payler 1984</a>), was the only identified potential bias in this review process. </p> </section> <section id="CD002745-sec-0086"> <h3 class="title" id="CD002745-sec-0086">Agreements and disagreements with other studies or reviews</h3> <p>Although another Cochrane review carried out in adults showed that both amantadine and rimantadine are efficacious and safe in the prophylaxis and treatment of influenza A symptoms (<a href="./references#CD002745-bbs2-0245" title="JeffersonT , DemicheliV , DiPietrantonjC , RivettiD . Amantadine and rimantadine for influenza A in adults. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD001169.pub3] ">Jefferson 2006b</a>), we could not reach the same conclusion in children and the elderly, except for prophylaxis with amantadine in children. This antiviral was effective in preventing influenza A in children. As in the adults review, rimantadine shortens the duration of fever in children. In 2012, the editorial team considered that the question addressed by this Cochrane review dealing with adults was no longer relevant to decision‐making, as amantadine and rimantadine for influenza A in adults had been replaced by neuraminidase inhibitors and were no longer used. </p> <p>The M2 ion channel inhibitors are increasingly subject to viral resistance (<a href="./references#CD002745-bbs2-0240" title="GoodmanC , MukherjeeD , FaulknerE . How effective would antiviral vaccination and antiviral drug prevention and treatment strategies be for reducing the impact of the next influenza pandemic. Copenhagen, WHO Regional Office for Europe (Health Evidence Network report; http://www.euro.who.int/en/data‐and‐evidence/evidence‐informed‐policy‐making/publications/pre2009/how‐effective‐would‐antiviral‐vaccination‐and‐antiviral‐drug‐prevention‐and‐treatment‐strategies‐be‐for‐reducing‐the‐impact‐of‐the‐next‐influenza‐pandemic 2006 (accessed 20 October 2007). ">Goodman 2006</a>; <a href="./references#CD002745-bbs2-0259" title="SleemanK , GuoZ , BarnesJ , ShawM , StevensJ , GubarevaL . R292K Substitution and drug susceptibility of Influenza A (H7N9) viruses. Emerging Infectious Diseases2013;9(9):1521‐4. ">Sleeman 2013</a>). Nevertheless, we consider that in these two especially vulnerable age groups, we should continue to assess the susceptibility of any influenza A outbreak virus to all antiviral drugs, as they may be the first line of defence before an effective vaccine becomes available (<a href="./references#CD002745-bbs2-0259" title="SleemanK , GuoZ , BarnesJ , ShawM , StevensJ , GubarevaL . R292K Substitution and drug susceptibility of Influenza A (H7N9) viruses. Emerging Infectious Diseases2013;9(9):1521‐4. ">Sleeman 2013</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002745-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002745-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full#CD002745-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002745-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full#CD002745-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Amantadine or rimantadine compared to placebo or acetaminophen in the treatment of influenza A in children, Outcome 1 Fever day 3." data-id="CD002745-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Amantadine or rimantadine compared to placebo or acetaminophen in the treatment of influenza A in children, Outcome 1 Fever day 3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Amantadine or rimantadine compared to placebo or acetaminophen in the treatment of influenza A in children, Outcome 2 Malaise day 6." data-id="CD002745-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Amantadine or rimantadine compared to placebo or acetaminophen in the treatment of influenza A in children, Outcome 2 Malaise day 6. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Amantadine or rimantadine compared to placebo or acetaminophen in the treatment of influenza A in children, Outcome 3 Cough day 7." data-id="CD002745-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Amantadine or rimantadine compared to placebo or acetaminophen in the treatment of influenza A in children, Outcome 3 Cough day 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Amantadine or rimantadine compared to placebo or acetaminophen in the treatment of influenza A in children, Outcome 4 Conjunctivitis day 5." data-id="CD002745-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Amantadine or rimantadine compared to placebo or acetaminophen in the treatment of influenza A in children, Outcome 4 Conjunctivitis day 5. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Amantadine or rimantadine compared to placebo or acetaminophen in the treatment of influenza A in children, Outcome 5 Eye symptoms day 5 (pain on movement and visual distortion)." data-id="CD002745-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Amantadine or rimantadine compared to placebo or acetaminophen in the treatment of influenza A in children, Outcome 5 Eye symptoms day 5 (pain on movement and visual distortion). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Amantadine and rimantadine compared to placebo and to specific treatment in the prophylaxis of influenza A in children, Outcome 1 Infection." data-id="CD002745-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Amantadine and rimantadine compared to placebo and to specific treatment in the prophylaxis of influenza A in children, Outcome 1 Infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amantadine and rimantadine compared to placebo in the prophylaxis of influenza A in the elderly, Outcome 1 RMT (proved and clinical infection)." data-id="CD002745-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Amantadine and rimantadine compared to placebo in the prophylaxis of influenza A in the elderly, Outcome 1 RMT (proved and clinical infection). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amantadine and rimantadine compared to placebo in the prophylaxis of influenza A in the elderly, Outcome 2 RMT Monto (100 + 200) and Patriarca." data-id="CD002745-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Amantadine and rimantadine compared to placebo in the prophylaxis of influenza A in the elderly, Outcome 2 RMT Monto (100 + 200) and Patriarca. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amantadine and rimantadine compared to placebo in the prophylaxis of influenza A in the elderly, Outcome 3 RMT 200." data-id="CD002745-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Amantadine and rimantadine compared to placebo in the prophylaxis of influenza A in the elderly, Outcome 3 RMT 200. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amantadine and rimantadine compared to placebo in the prophylaxis of influenza A in the elderly, Outcome 4 RMT 100." data-id="CD002745-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Amantadine and rimantadine compared to placebo in the prophylaxis of influenza A in the elderly, Outcome 4 RMT 100. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Use of different doses of rimantadine for prophylaxis and treatment of influenza A in the elderly, Outcome 1 Clinical and laboratory infection." data-id="CD002745-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Use of different doses of rimantadine for prophylaxis and treatment of influenza A in the elderly, Outcome 1 Clinical and laboratory infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rimantadine compared to zanamivir in the elderly, Outcome 1 RMT and zanamivir." data-id="CD002745-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Rimantadine compared to zanamivir in the elderly, Outcome 1 RMT and zanamivir.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 1 Diarrhoea." data-id="CD002745-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 1 Diarrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 2 Exanthema." data-id="CD002745-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 2 Exanthema. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 3 Muscular, limb pain." data-id="CD002745-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 3 Muscular, limb pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 4 Headache." data-id="CD002745-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 4 Headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 5 Stimulation/insomnia." data-id="CD002745-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 5 Stimulation/insomnia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 6 Dizziness." data-id="CD002745-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 6 Dizziness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 7 Dyspnoea." data-id="CD002745-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 7 Dyspnoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 8 Central nervous system symptoms." data-id="CD002745-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 8 Central nervous system symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 9 Change in behaviour." data-id="CD002745-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 9 Change in behaviour. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 10 Gastrointestinal symptoms." data-id="CD002745-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 10 Gastrointestinal symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 11 Hyperreactivity." data-id="CD002745-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 11 Hyperreactivity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 12 Tinnitus." data-id="CD002745-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 12 Tinnitus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 13 Cerebellar ataxia." data-id="CD002745-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 13 Cerebellar ataxia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 14 Malaise." data-id="CD002745-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 14 Malaise. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 15 Nausea/vomiting." data-id="CD002745-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 15 Nausea/vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-006-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-006-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 16 Arrhythmia." data-id="CD002745-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.16</div> <div class="figure-caption"> <p>Comparison 6 Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children, Outcome 16 Arrhythmia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-006-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 1 Stimulation/insomnia." data-id="CD002745-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 1 Stimulation/insomnia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 2 Confusion." data-id="CD002745-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 2 Confusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 3 Fatigue." data-id="CD002745-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 3 Fatigue. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 4 Vomiting." data-id="CD002745-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 4 Vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 5 Headache." data-id="CD002745-fig-0035" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 5 Headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 6 Impaired concentration." data-id="CD002745-fig-0036" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 6 Impaired concentration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 7 Rash or allergic reaction." data-id="CD002745-fig-0037" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 7 Rash or allergic reaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-007-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-007-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 8 Seizures or clonic twitching." data-id="CD002745-fig-0038" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 8 Seizures or clonic twitching. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-007-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-007-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 9 Dry mouth." data-id="CD002745-fig-0039" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 9 Dry mouth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-007-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-007-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 10 Dizziness." data-id="CD002745-fig-0040" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 10 Dizziness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-007-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-007-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 11 Anxiety." data-id="CD002745-fig-0041" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.11</div> <div class="figure-caption"> <p>Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 11 Anxiety. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-007-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-007-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 12 Nausea." data-id="CD002745-fig-0042" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.12</div> <div class="figure-caption"> <p>Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 12 Nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-007-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-007-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 13 Depression." data-id="CD002745-fig-0043" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.13</div> <div class="figure-caption"> <p>Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 13 Depression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-007-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-007-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 14 Loss of appetite." data-id="CD002745-fig-0044" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.14</div> <div class="figure-caption"> <p>Comparison 7 Adverse effects of rimantadine compared to placebo in the elderly, Outcome 14 Loss of appetite. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-007-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 1 Confusion." data-id="CD002745-fig-0045" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 1 Confusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 2 Depression." data-id="CD002745-fig-0046" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 2 Depression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 3 Impaired concentration." data-id="CD002745-fig-0047" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 3 Impaired concentration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 4 Insomnia or sleeplessness." data-id="CD002745-fig-0048" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 4 Insomnia or sleeplessness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 5 Loss of appetite." data-id="CD002745-fig-0049" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 5 Loss of appetite. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 6 Rash or allergic reaction." data-id="CD002745-fig-0050" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 6 Rash or allergic reaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 7 Seizure or clonic twitching." data-id="CD002745-fig-0051" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 7 Seizure or clonic twitching. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 8 Dry mouth." data-id="CD002745-fig-0052" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 8 Dry mouth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 9 Fatigue and drowsiness." data-id="CD002745-fig-0053" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 9 Fatigue and drowsiness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-008-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-008-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 10 Headache." data-id="CD002745-fig-0054" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 10 Headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-008-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-008-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 11 Body weakness or debility." data-id="CD002745-fig-0055" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8 Adverse effects related to different doses of rimantadine in the elderly, Outcome 11 Body weakness or debility. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-008-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002745-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/urn:x-wiley:14651858:media:CD002745:CD002745-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_t/tCD002745-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Additional comparison: RMT compared to placebo in the prophylaxis of influenza A in children and the elderly, Outcome 1 Infection." data-id="CD002745-fig-0056" src="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Additional comparison: RMT compared to placebo in the prophylaxis of influenza A in children and the elderly, Outcome 1 Infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/media/CDSR/CD002745/image_n/nCD002745-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002745-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Amantadine compared with placebo for prevention and treatment of influenza A in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with no influenza A infection (prevention) or with influenza A infection (treatment) </p> <p><b>Settings:</b> all </p> <p><b>Intervention:</b> amantadine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Amantadine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cases of influenza A during prophylaxis</b> </p> <p>(follow‐up:14 to 18 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.11</b> (0.04 to 0.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>773<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> <br/> (0 to 3) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fever after initiation of treatment</b> </p> <p>(follow‐up: 3 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.37</b> (0.08 to 1.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>104<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 100</b> <br/> (2 to 40) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cough after initiation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dizziness</b> </p> <p>(follow‐up: 7 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 6.63</b> (0.32 to 137.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>599<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nausea/vomiting</b> </p> <p>(follow‐up: 7 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.54</b> (0.15 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>599<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>3,4,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> <br/> (2 to 27) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stimulation/insomnia</b> </p> <p>(follow‐up: 7 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.46</b> (0.12 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>599<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>3,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> <br/> (2 to 27) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) was calculated on the basis of control event rate. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><sup>1</sup>Allocation concealment not used or unclear. </p> <p><sup>2</sup>Sparse data. </p> <p><sup>3</sup>Allocation concealment unclear. </p> <p><sup>4</sup>Sparse data, confidence intervals do not rule out potential for null effect or harm. </p> <p><sup>5</sup>High heterogeneity unexplained. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full#CD002745-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002745-tbl-0002"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Rimantadine compared with placebo for prevention and treatment of influenza A in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with no influenza A infection (prevention) or with influenza A infection (treatment) </p> <p><b>Settings:</b> any </p> <p><b>Intervention:</b> rimantadine </p> <p><b>Comparison:</b> control (placebo or acetaminophen) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Rimantadine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cases of influenza A during prophylaxis</b> (follow‐up: 1 to 35 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.49</b> (0.21 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>178<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 100</b> <br/> (5 to28) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fever after initiation of treatment</b> </p> <p>(follow‐up: 3 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.36</b> (0.14 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>69<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b> <br/> (5 to 34) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cough after initiation of treatment</b> </p> <p>(follow‐up: 7 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b> (0.63 to 1.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>69<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 100</b> <br/> (51 to 89) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dizziness</b> </p> <p>(follow‐up: 35 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.21</b> (0.14 to 75.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>56<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 100</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nausea/vomiting</b> </p> <p>(follow‐up: 7 to 35 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.96</b> (0.1 to 9.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b> <br/> (0 to 15) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stimulation/insomnia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) was calculated on the basis of control event rate. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><sup>1</sup>Allocation concealment unclear. </p> <p><sup>2</sup>Sparse data and confidence intervals do not rule out the potential for no effect or harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full#CD002745-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002745-tbl-0003"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Amantadine compared with placebo for prevention and treatment of influenza A in the elderly</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> elderly people with no influenza A infection (prevention) or with influenza A infection (treatment) </p> <p><b>Settings:</b> any </p> <p><b>Intervention:</b> amantadine </p> <p><b>Comparison:</b> control </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Amantadine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases of influenza A during prophylaxis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever after initiation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cough after initiation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dizziness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vomiting</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stimulation/insomnia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full#CD002745-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002745-tbl-0004"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> elderly people with no influenza A infection (prevention) or with influenza A infection (treatment) </p> <p><b>Settings:</b> any </p> <p><b>Intervention:</b> rimantadine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Rimantadine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cases of influenza A during prophylaxis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.45</b> (0.14 to 1.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>103<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> <br/> (2 to 23) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever after initiation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cough after initiation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No selected trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dizziness</b> </p> <p>(follow‐up: 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 100 (2 to 70)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/> (0.15 to 5.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nausea</b> </p> <p>(follow‐up: 8 to 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.99</b> (0.45 to 8.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>233<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 100</b> <br/> (3 to 66) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Vomiting</b> </p> <p>(follow‐up: 8 to 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.99</b> (0.38 to 2.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>233<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> <br/> (3 to 17) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stimulation/insomnia</b> (follow‐up: 8 to 12 weeks) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.61</b> (0.43 to 6.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>233<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 100</b> <br/> (3 to 40) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) was calculated on the basis of control event rate. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><sup>1</sup>Allocation concealment unclear and 1 study had high withdrawal rate. </p> <p><sup>2</sup>Sparse data and confidence interval do not rule out no effect or harm. </p> <p><sup>3</sup>Allocation concealment unclear </p> <p><sup>4</sup>High heterogeneity unexplained. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/full#CD002745-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002745-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Amantadine or rimantadine compared to placebo or acetaminophen in the treatment of influenza A in children</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fever day 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 AMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.08, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.14, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Malaise day 6 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.63, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cough day 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.63, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.63, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Conjunctivitis day 5 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Eye symptoms day 5 (pain on movement and visual distortion) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.10, 3.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Amantadine or rimantadine compared to placebo or acetaminophen in the treatment of influenza A in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002745-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Amantadine and rimantadine compared to placebo and to specific treatment in the prophylaxis of influenza A in children</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.09, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 AMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.04, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.21, 1.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Amantadine and rimantadine compared to placebo and to specific treatment in the prophylaxis of influenza A in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002745-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Amantadine and rimantadine compared to placebo in the prophylaxis of influenza A in the elderly</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 RMT (proved and clinical infection) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.13, 4.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 RMT Monto (100 + 200) and Patriarca <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.14, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 RMT 200 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.12, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 RMT 100 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.10, 21.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Amantadine and rimantadine compared to placebo in the prophylaxis of influenza A in the elderly</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002745-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Use of different doses of rimantadine for prophylaxis and treatment of influenza A in the elderly</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical and laboratory infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.21, 4.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.21, 4.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Use of different doses of rimantadine for prophylaxis and treatment of influenza A in the elderly</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002745-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Rimantadine compared to zanamivir in the elderly</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 RMT and zanamivir <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.63 [1.46, 14.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Rimantadine compared to zanamivir in the elderly</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002745-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.42, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 AMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.43, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.02, 8.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Exanthema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.21, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 AMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.21, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Muscular, limb pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.46, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 AMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.46, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.52, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 AMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.52, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Stimulation/insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.12, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 AMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.12, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.69 [0.53, 41.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 AMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.63 [0.32, 137.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [0.14, 75.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Dyspnoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.02, 9.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 AMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.02, 9.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Central nervous system symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 4.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 4.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Change in behaviour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 4.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 4.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Gastrointestinal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.08, 18.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.08, 18.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Hyperreactivity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.02, 8.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.02, 8.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Tinnitus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [0.14, 75.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [0.14, 75.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Cerebellar ataxia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.61 [0.11, 61.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.61 [0.11, 61.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Malaise <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.41, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 AMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.41, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Nausea/vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.24, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 AMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.15, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.10, 9.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Arrhythmia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 AMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002745-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Adverse effects of rimantadine compared to placebo in the elderly</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Stimulation/insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.43, 6.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.43, 6.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Confusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.40, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.40, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.41, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.41, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.38, 2.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.38, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.21, 3.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.21, 3.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Impaired concentration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.10, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.10, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Rash or allergic reaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.53 [0.18, 67.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.53 [0.18, 67.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Seizures or clonic twitching <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.23, 17.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.23, 17.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Dry mouth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.7 [0.23, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.7 [0.23, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.15, 5.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.15, 5.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [0.92, 8.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [0.92, 8.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [0.45, 8.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [0.45, 8.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.53, 4.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.53, 4.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Loss of appetite <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.56, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.56, 2.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Adverse effects of rimantadine compared to placebo in the elderly</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002745-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Adverse effects related to different doses of rimantadine in the elderly</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Confusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.41, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.41, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.12, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.12, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Impaired concentration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.11, 3.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.11, 3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Insomnia or sleeplessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.26, 3.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.26, 3.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Loss of appetite <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.27, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.27, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Rash or allergic reaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.04, 3.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.04, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Seizure or clonic twitching <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Dry mouth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.43, 3.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.43, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Fatigue and drowsiness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.45, 2.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.45, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.30, 3.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.30, 3.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Body weakness or debility <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.38, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.38, 2.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Adverse effects related to different doses of rimantadine in the elderly</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002745-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Additional comparison: RMT compared to placebo in the prophylaxis of influenza A in children and the elderly</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.27, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 RMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.27, 0.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Additional comparison: RMT compared to placebo in the prophylaxis of influenza A in children and the elderly</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002745.pub4/references#CD002745-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002745.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002745-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002745-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002745-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD002745-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD002745-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002745\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002745\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002745\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002745\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002745\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002745.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002745.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002745.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002745.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002745.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714446129"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002745.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714446133"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002745.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6edb19d89377',t:'MTc0MDcxNDQ0Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 